

Catecholamine Studies May Differentiate Depressed Patients

BY ANASTASIA TOUPEXIS
Medical Tribune Staff

BOSTON—Clinical measurements of catecholamine metabolism may eventually help doctors differentiate among the subtypes of depression, according to Harvard psychiatrist Joseph J. Schildkraut.

Recent findings appear to support the hypothesis, first suggested in 1965, that "various measures related to catecholamine metabolism may provide a clinically useful biochemical basis for classifying the depressive disorders," Dr. Schildkraut told a symposium here on depression, sponsored by McLean Hospital, Belmont, Mass.

The findings, which come out of joint studies by Harvard Medical

School's psychiatry department, McLean Hospital, and the Neuropsychopharmacology Laboratory of the Massachusetts Mental Health Center, include the following:

- Urinary excretion of 3-methoxy-4-hydroxyphenylglycol (MHPG), the major metabolite of norepinephrine originating in the brain, was significantly higher in unipolar depressives compared to bipolar manic-depressive and schizoaffective patients.

- A depression type score (derived from multiple discriminant function analysis of urinary catecholamines and metabolites) distinguished accurately between unipolar patients and those with bipolar and schizoaffective illness. In addition, the score was helpful in

identifying depressed patients with a latent predisposition to bipolar illness before appearance of the first manic or hypomanic episode, according to Dr. Schildkraut.

- Platelet monoamine oxidase activity was useful in making "clinically relevant distinctions within the group of depressed patients with relatively low MHPG excretion," Dr. Schildkraut said. The combination of high platelet monoamine oxidase activity and low MHPG excretion was associated with patients who had histories of chronic affective, eccentric or bizarre behavior and experienced psychosis when treated with tricyclic antidepressants.

The differential point in urinary MHPG excretion levels appears to be

1500 µg/day, Dr. Schildkraut indicated. "Considering the total sample of 37 depressed patients, we found that 13 of the 15 patients with schizoaffective or bipolar manic-depressive depressions had MHPG levels less than 1500 µg/day, whereas in 12 of the 13 patients with unipolar chronic characterological or unipolar nonspecific depressions the levels of MHPG were 1500 µg/day or higher," he said.

Dr. Schildkraut noted that three patients thought to have unipolar endogenous depression had MHPG levels below 1500 µg/day. The low MHPG level suggests that some unipolar endogenous depressives may be "biochemically heterogeneous" or that these patients were actually latent bipolar depressives, incorrectly classified as unipolar because a manic episode had not yet occurred, Dr. Schildkraut said.

The researchers found that the MHPG difference between depression subtypes could not be explained by differences in severity of depression, sex, age, urine volume or creatinine excretion.

Although other urinary catecholamines and metabolites were measured, including norepinephrine, normetanephrine, epinephrine, metanephrine and 3-methoxy-4-hydroxymandelic acid (VMA), "only MHPG showed highly significant differences among the subgroups of depressive disorders," Dr. Schildkraut reported.

However, the researchers could not rule out the possibility that the other urinary metabolites might also contain useful information. Using urine metabolite data, a discrimination equation was developed which produced characteristic scores for depression types.

Precise Differences

In this formulation, low scores (below 0.500) were related to bipolar manic depression and high scores (above 0.500) to chronic unipolar depression, Dr. Schildkraut said.

One patient, considered to have a unipolar disorder, scored 0.381. "One year after the biochemical studies were performed, this patient experienced his first hypomanic episode," Dr. Schildkraut noted.

"The present findings suggest that this equation may provide an even more precise discrimination between these types of depressive disorders than does urinary MHPG alone," he said.

Preliminary findings with 25 patients suggest that "relatively high platelet monoamine oxidase activity (greater than 7 nanomoles tryptamine deaminated/hr/mg protein) in conjunction with low MHPG excretion (less than 1500 µg/day) may help to discriminate a further subgroup of depressive disorders, characterized clinically by histories of chronic affective, eccentric or bizarre behavior and the propensity for psychotic disorganization (clinically distinguishable from hypomanic or manic states), particularly when treated with tricyclic antidepressant drugs."

"In contrast depressed patients with low MHPG and relatively low platelet monoamine oxidase activity may constitute another subgroup of depressive disorders that includes bipolar manic-depressive and related disorders."

77% of U.S. Family Physicians Would Consider Passive Euthanasia

Medical Tribune Report

What do American family physicians think of euthanasia today? The results of a major poll, conducted by Medical Tribune and published in this issue, provide what may be the most reliable answer. An identical survey of French general practitioners' attitudes, sponsored by La Tribune

Médical, appeared on these pages last week.

What might be the expected differences between the two populations? Euthanasia is unquestionably a significant issue throughout the Western world, but nowhere more so than in the United States, with its vast arm-

Have you had a terminally ill patient ask you to cut short his suffering?

	TOTAL	Age of Physicians		
		35 years and less	36 to 50 years	Over 50 years
Yes	57%	33%	54%	60%
No	43%	67%	46%	40%

Continued on page 19

Medical Tribune

© 1976, Medical Tribune, Inc.

and Medical News

Vol. 17, No. 20

world news of medicine and its practice—fast, accurate, complete

Wednesday, May 26, 1976

If there's good reason to prescribe for psychic tension...



When, for example,
reassurance and counseling
on repeated visits
are not enough

Effectiveness is a good reason to consider Valium® (diazepam) [®]

2-mg, 5-mg, 10-mg tablets

Before prescribing, please consult complete product information, a summary of which follows:

Indications: Tension and anxiety states; somatic complaints which are concomitants of emotional factors; psychoneurotic states manifested by tension, anxiety, apprehension, fatigue, depressive symptoms or agitation; symptomatic relief of acute agitation, tremor, delirium tremens and hallucinosis due to acute alcohol withdrawal; adjunctively in skeletal muscle spasm due to reflex spasm to local pathology, spasticity caused by upper motor neuron disorders, athetosis, stiff-man syndrome, convulsive disorders (not for sole therapy).

Contraindications: Known hypersensitivity to the drug. Children under 6 months of age. Acute narrow angle glaucoma; may be used in patients with open angle glaucoma who are receiving appropriate therapy.

Warnings: Not of value in psychotic patients. Caution against hazardous occupations requiring complete mental alertness. When used adjunctively in convulsive disorders, possibility of increase in frequency and/or severity of grand mal seizures may require increased dosage of standard anticonvulsant medication; abrupt withdrawal may be associated with temporary increase in frequency and/or severity of seizures. Advise against simultaneous ingestion of alcohol and other CNS depressants. Withdrawal symptoms (similar to those with barbiturates and alcohol) have occurred following abrupt discontinuance (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating). Keep addiction-prone individuals under careful surveillance because of their predisposition to habituation and dependence. In pregnancy, lactation or women of childbearing age, weigh potential benefit against possible hazard.

Precautions: If combined with other psychotropics or anticonvulsants, consider carefully pharmacology of agents employed; drugs such as phenothiazines, narcotics, barbiturates, MAO inhibitors and other antidepressants may potentiate its action. Usual precautions indicated in patients severely depressed, or with latent depression, or with suicidal tendencies. Observe usual precautions in impaired renal or hepatic function. Limit dosage to smallest effective amount in elderly and debilitated to preclude ataxia or oversedation.

Side Effects: Drowsiness, confusion, diplopia, hypotension, changes in libido, nausea, fatigue, depression, dysarthria, jaundice, skin rash, ataxia, constipation, headache, incontinence, changes in salivation, slurred speech, tremor, vertigo, urinary retention, blurred vision. Paradoxical reactions such as acute hyperexcited states, anxiety, hallucinations, increased muscle spasticity, insomnia, rage, sleep disturbances, stimulation have been reported; should these occur, discontinue drug. Isolated reports of neutropenia, jaundice, periodic blood counts and liver function tests advisable during long-term therapy.

Roche Laboratories, Inc.
Division of Hoffmann-La Roche, Inc.
Nutley, N.J. 07110

Diabetes Assn. Says:

Control of Sugar In Blood Is Main Goal of Therapy

By NATHAN H. LITWITZ
Medical Tribune Staff

NEW YORK—In a major policy statement, the American Diabetes Association has declared that blood sugar control should be a principal goal of diabetic therapy, and has urged physicians to aim for blood glucose levels in the diabetic "as close to the non-diabetic as possible."

Taking its stand on an issue that has been a center of controversy among endocrinologists for almost 50 years, the ADA said the cumulative data of animal studies, biochemical studies in man and at least one prospective study all point to the conclusion that prolonged hyperglycemia is a factor in the microvascular complications of diabetes.

Continued on page 14

'Spectacular' Results

Cerium Ointment Seen Preventing Burn Infections


Medical Tribune Report

SAN ANTONIO—Cerium nitrate has a significant bacteriostatic effect on major burn wounds, a Missouri investigator reported here. A 2.2% concentration of the compound mixed into a silver sulfadiazine cream was particularly effective against gram negative bacteria, including *Pseudomonas aeruginosa*, in a study by Dr. William Monafio, of St. Louis Mercy Medical Center, St. Louis. *Pseudomonas*, he reported, was found in less than 10% of cultures.

"Reviewing our past ten-year period

Continued on page 17

Improved Mammography Lowers Radiation Dose



Above mammograms of the same patient show comparable diagnostic quality but at greatly different radiation dosage per exposure. At left, Xeromammogram positive was taken at approximately 900 mR. The corresponding Xeromammogram negative was made at patient exposure of 50 mR. Clinical studies of the XERG process are underway at Los Angeles County-USC Medical Center. See story on page 5.

Electron Radiography System (XERG) negative mammogram was made at patient exposure of 50 mR. Clinical studies of the XERG process are underway at Los Angeles County-USC Medical Center. See story on page 5.

BCG Therapy Successful in Early Lung Ca

By JOHN HENAHAN
Special Tribune Correspondent

LOS ANGELES—The reportedly successful use of the immunotherapeutic agent BCG in the treatment of 24 patients with Stage I lung cancer was greeted by one scientist as "a milestone in lung cancer therapy" at the 56th annual meeting of the American Association for Thoracic Surgery held here.

Only one of the 25 Stage I lung cancer patients who received a single dose

of BCG interpleurally after surgery showed a recurrence of the disease over a median 12-month span as compared to nine recurrences and nine deaths in a group of 25 lung cancer patients who did not receive BCG. No deaths were observed in the BCG-treated Stage I lung cancer patients, said Dr. Martin F. McKneally, of the Albany Medical College, Albany, N.Y.

In the same trial, patients with Stage II and Stage III lung cancer appeared

to receive no appreciable benefit from BCG therapy, he added, suggesting that the heavy tumor burden, along with a breakdown of immune defenses, may outstrip the ability of BCG to protect more advanced lung cancer patients from the inroads of the disease.

Each of the patients in the study group received an interpleural injection of 10 million BCG organisms via a chest tube after surgery. The BCG the

Continued on page 23

Sitting pretty for years to come...

Gentle in bringing patients down to normotensive levels, Esidrix will continue to "sit right" with many of the mild hypertensives for whom you prescribe it. Indeed, it can mean years and years of even, uneventful control.

Esidrix. It is still unsurpassed as a basic diuretic/antihypertensive.

And many patients with edema rarely need a more potent diuretic.

Contraindications include anuria. Use cautiously in patients with impaired renal or hepatic function.



Esidrix[®] (hydrochlorothiazide) for year-after-year control of mild hypertension

Esidrix[®] (hydrochlorothiazide)

INDICATIONS
Hypertension and edema.

CONTRAINDICATIONS
Anuria; hypersensitivity to this or other sulfonamide-derived drugs. The routine use of diuretics in an otherwise healthy pregnant woman with or without mild edema is contraindicated and possibly hazardous.

WARNINGS
Use with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function. Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Thiazides may be additive or potentiative of the action of other antihypertensive drugs. Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.

Sensitivity reactions are more likely to occur in patients with a history of allergy or bronchial asthma. The possibility of exacerbation or activation of systemic lupus erythematosus has been reported.

Usage in Pregnancy
Usage of thiazides in women of childbearing age requires that the potential benefits of the drug be weighed against its possible hazards to the fetus. These hazards include fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions which have occurred in the adult.

Nursing Mothers
Thiazides cross the placental barrier and appear in cord blood and breast milk.

PRECAUTIONS
Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals. Observe patients for clinical signs of fluid or electrolyte imbalance (hyponatremia, hypochloremic alkalosis, and hypokalemia). Serum and urine electrolyte determinations are particularly important when the patient is vomiting excessively or receiving parenteral fluids. Medication such as digitalis may also influence serum electrolytes. Warning signs are dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, alguria, tachycardia, and gastrointestinal disturbance such as nausea or vomiting.

Hypokalemia may develop with thiazides as with any other potent diuretic, especially during brisk diuresis, when severe cirrhosis is present, or during concomitant administration of steroids or ACTH. Interference with adequate oral intake of electrolytes will also contribute to hypokalemia. Digitalis therapy may exaggerate metabolic effects of hypokalemia, especially with reference to myocardial activity.

Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or renal disease). Dilutional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction rather than administration of salt, except in rare instances when the hy-

ponatremia is life-threatening, in actual salt depletion; appropriate replacement is the therapy of choice.

Transient elevations in plasma calcium may occur in patients receiving thiazides, particularly in those with hyperparathyroidism. Pathological changes in the parathyroid gland have been reported in a few patients on prolonged thiazide therapy.

Hypertension may occur or frank gout may be precipitated in certain patients. Insulin requirements in diabetic patients may be increased, decreased, or unchanged. Latent diabetes may become manifest during thiazide administration.

Thiazide drugs may increase the responsiveness to tuberculin. The antihypertensive effects of the drug may be enhanced in the post-sympathectomy syndrome to norepinephrine. This is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.

It is important to consider withholding or discontinuing diuretic therapy.

Thiazides may decrease serum FBT levels without signs of thyroid disturbance.

ADVERSE REACTIONS
Gastrointestinal—nausea, gastric irritation, nausea, vomiting, cramping, diarrhea, constipation, indigestion, flatulence, dyspepsia, pancreatitis.

Central Nervous System—dizziness, vertigo, paraesthesia, headache, xanthopsia, dermatologic: urticaria, necrotizing angitis, Stevens-Johnson syndrome, and other hypersensitivity reactions.

Hematologic—leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia, cardiovascular: orthostatic hypotension may occur and may be potentiated by alcohol, glycosuria, hyperuricemia, Other—hyperglycemia, glycosuria, hyperuricemia, muscle spasm, weakness, restlessness. Moderate adverse reactions are moderate or severe, restlessness, or withdrawal therapy.

DOSEAGE
Individualize dosage by titrating for maximum therapeutic response at the lowest possible dose.

Hypertension—Initial—Usual dosage may be 25 mg daily. Maintenance—After a week dosage may be adjusted downward to as little as 25 mg or upward to as much as 100 mg daily. Combined therapy with other antihypertensive agents may be added gradually and with caution because of the potentiating effect of this drug. Dosage of parenteral blockers should be halved.

Edema—Initial—25 to 100 mg daily or 100 mg daily. Maintenance—25 to 100 mg daily or 100 mg daily. Refractory patients may require up to 200 mg daily.

SUPPLIED
Tablets, 50 mg (yellow, scored); bottles of 50, 100, 1000, 5000, and Accu-Pak blister unit of 100. Tablets, 25 mg (pink, scored); bottles of 50, 100, 1000 and 5000.

Consult complete literature before prescribing. CIBA Pharmaceutical Company, Division of CIBA-GEIGY Corporation, Summit, New Jersey 07901.

CIBA

30000 17

Wednesday, May 26, 1976

'Liquid Membrane' May Counter Overdose

By MICHAEL HERRING
Medical Tribune Staff

New York—A "milkshake" of "liquid membrane" capsules may one day be all that is needed to save the lives of thousands of children and other drugs for overdose aspirin and other drugs for overdose, according to scientists at the American Chemical Society meeting here.

Liquid membranes—made by encapsulating one solution within another by means of "surfactant molecules that hold the liquid film in place"—may also eventually be used to treat drug overdoses of all kinds, remove blood toxins in chronic uremia, oxygenate blood, control drug release, and remove heavy metals from waste water, according to Norman N. Li, Ph.D.


Dr. Li, a research scientist at Exxon Research Engineering Company who discovered liquid membranes "by chance laboratory observation" in 1966, explained how they work, using water and oil as a model. The surfactant molecules, he said, have a hydrophobic head and a hydrophilic tail and serve "as nails" to stabilize the membrane.

Making the Membranes

"To make a liquid membrane, you dissolve the surfactant into the water phase, then cover a droplet of oil with the water film. Then you add another phase, the external or continuous phase, so you end up with the oil droplet, water film and an oil phase on the outside."

To achieve more surface area, Dr. Li and others have made liquid membranes of micron size, and these are changed in globules or aggregates of tiny liquid membrane capsules (LMC), he said.

John W. Frankenfeld, Ph.D., a sen-



Liquid membranes, above l. and r., are held together by surfactant molecules, top of diagram. The molecule, with affinity for water at one end and oil at the other, acts as a staple to encapsulate oil within water film, or vice versa. Other liquids may be used, and capsules of micron size are possible.

ior research scientist at Exxon, said the liquid capsules have already shown "considerable potential" for removing toxins from gut fluid. "We have removed 95% of aspirin and phenobarbital from in vitro gut-fluid suspensions in less than five minutes," he reported.

In this case, sodium hydroxide is encapsulated in an oil membrane and suspended in gut fluid containing the highly acidic drugs, he said. As the drugs permeate the oil film, they are ionized by the NaOH and are no longer oil soluble, but trapped by the membrane. "Since intestinal absorption is considerably slower, LMC treatment within an hour or two of drug ingestion should be quite effective."

The trapped ions, he said, would be eliminated in the stool, and patients would not have to endure the uncertain

sequelae of current emergency measures. "Drugs do not have to be oil soluble," he also noted. "We can put reagents in the film [e.g., plasma proteins, drug antibodies, activated charcoal, etc.] that will dissolve non-oil-soluble and even ionized materials." Animal studies are next, he said, with clinical trials in man about two years off.

Tested in Uremia

The use of LMCs as an adjunct to dialysis in chronic uremia is already being tested in animals, according to William Asher, also of Exxon, and his physician colleagues at the University of Pennsylvania. "The frequency of required dialyses... might be reduced if the program is successful," Mr. Asher told the press.

"The approach is to transfer the tox-

Continued on page 23

New Heroin Addicts Held More Treatment Resistant Than Oldtimers

By NATHAN HORWITZ
Medical Tribune Staff

PHILADELPHIA—A new type of heroin addict, more resistant to treatment than earlier drug abusers, is entering "the competitive market for addiction" in Philadelphia, a major study reports.

The changing drug picture in 1974-1975 shows the new addict is more depressed, starts with heroin as his first drug of addiction, has been in previous treatment, has a longer arrest record, and more often comes from a family in which one or both parents are dead.

These findings were highlights of the fourth successive survey of Philadelphia drug addicts detailed here by Dr. Jacob Schut, director of the Drug Abuse Rehabilitation Program of the West Philadelphia Mental Health Con-

increase in the number of addicts seeking admission [to the treatment programs].

Fewer of the admissions in the early seventies, Dr. Schut reported, had been in treatment compared to those in the 1973-1975 admissions. One explanation for that, he said, may be the fact that Philadelphia's Central Medical Intake now assigns addicts to a methadone program only when other types of treatment have failed, but this is counter-balanced by the existence of a variety of drug treatment programs currently available to addicts.

"It is well known that addicts 'shop' around for programs," the investigator said, "and there is a high incidence of readmissions, approximately 25% for this methadone program."

More Depressed

Thus a "more therapeutically resistant type of heroin addict seems to have emerged in 1974 and 1975, as opposed to the earlier seventies," he continued.

"This type of male addict comes from a family in which one or both parents were dead [during the addict's childhood], used heroin as his first drug of addiction and had been arrested often." He added: "Psychological and

clinical data seem to indicate that our present addicts are more depressed, with more overt symptoms than earlier patients."

Another new finding, Dr. Schut disclosed, is a shift in the addict's primary source of income, away from welfare funds and unemployment checks, suggesting that families are now supporting the patients.

"The earlier admissions had described themselves as more dependent on public support than the latter two years' admissions. This finding was puzzling, since the rate of unemployment had remained high and was consistent over the six years," declared Dr. Schut. "A turning towards family members for support seemed to have accented for the 1974 and 1975 shift; the increased incidence in the number of dead parents reported for admissions in these years meant that spouses and other relatives were paying for the addicts' support."

One of the unexplained observations, he noted, was that in contrast with 1972-1974, which showed an increase in female addicts, the number of female admissions last year dropped to the lower rate of 1970.

index

CLINICAL NEWS NOTE: "Current clinical and experimental data clearly demonstrate that optimal regulation of glucose levels should be achieved in the treatment of diabetes, particularly in young and middle-aged individuals who are at greatest risk of developing microvascular complications." (From official policy statement of the American Diabetes Assn. See page 1.)

Medicine: 1, 3, 5, 6, 7, 14, 18

Passive euthanasia considered by 77% of U.S. family physicians 1
Blood sugar control is therapy's main goal, says American Diabetes Assn. ... 1
Burn infections prevented by cerium nitrate ointment 1
BCG immunotherapy successful in early lung cancer 1
Drug overdose may be countered by "liquid membrane" 3
Heroin addicts now more treatment resistant than before 3
Improved mammography techniques lower radiation dosage 5
Human skin cells grown in laboratory 5
Arthritic pain reduced by low electric current applied to skin 5
Alcoholism termed Soviet's "real ideology" 6
Wrist motion restored by implanted joint 7
Infrared heat helps burn victims control hypermetabolism 14
Snakebite successfully treated with neostigmine 18

Pediatrics: 7

High risk infant survival improved by mandatory intermittent respiratory aid 7
Erythromycin is higher in child's serum if given after meals 7

feature index

Pediatric Progress 5
Editorials 11
Letters to Tribune 11
Ellet January 17
One Man and Medicine 17
Wine Talk 18
Immunization Medicine 23

Medical Tribune

CHRIS WOODBURY, Ph.D.
General Manager

HARRY HENDERSON RICHARD GUERNER, M.D.
Editor-in-Chief Associate Editor

HAROLD FOSNOT
Executive News Editor

JOHN H. HEWITT NATHAN HORWITZ
Associate News Editor Special News Editor

WILLIAM PRUITTS ANN CONNER
Art Supervisor Picture Editor

ARTHUR M. SACKLER, M.D.
International Publisher

Advisory Board
JOHN ADRIANI, M.D. • RENE J. DUBOS, Ph.D.
JULIUS H. MARRERMAN, M.D.

BERNARD LOWN, M.D.
ALTON OCHSNER, M.D.
LEO G. ROLER, M.D.

880 Third Avenue, New York, N.Y. 10022
Telephone (212) 421-4000


Circulation audited by Business Publications Audit of Circulation, Inc.

Medical Tribune is published each Wednesday except on March 31, June 6, June 16, June 30, July 14, Dec. 22, Dec. 11, Aug. 23, Sep. 29, Dec. 1, Dec. 22, Dec. 29, by Medical Tribune, Inc., 880 Third Ave., New York, N.Y. 10022. Controlled circulation postage paid at New York, N.Y. 08360 Subscription \$25.00, Students \$7.50.

MELLARIL® (THIORIDAZINE)

TABLETS: 10 mg, 15 mg, and 25 mg thioridazine HCl, U.S.P.

IN CLINICALLY SIGNIFICANT DEPRESSIVE NEUROSIS— RESULTS OFTEN SEEN IN A WEEK



Mellaril can often help you give patients with depressive neurosis relief within a week. In 14 double-blind studies of four weeks duration, 339 patients with depressive neurosis received Mellaril. In these studies, 55% of the overall improvement was observed by the end of the first week, and a total of 293 patients (86%) improved during the four weeks.*

With Mellaril, patients often have an end to such symptoms as insomnia, G.I. symptoms, irritability, defecation, and hopelessness before they have a chance to become entrenched.

*Data on file at Sandoz Pharmaceuticals.

Mellaril® (thioridazine)
short-term therapy of moderate
to marked depression with variable
degrees of anxiety in patients
with depressive neurosis

Before prescribing or administering, see Sandoz literature for full product information. The following is a brief summary.

Contraindications: Severe central nervous system depression; comatose states from any cause; hypersensitivity or hypotensive heart disease of extreme degree.

Warnings: Administer cautiously to patients who have previously exhibited a hypersensitivity reaction (e.g., blood dyscrasias, jaundice) to phenothiazines. Phenothiazines are capable of potentiating central nervous system depressants (e.g., anesthetics, opiates, alcohol, etc.), as well as of blocking and potentiating inotropic agents; carefully consider benefits versus risks in less severe disorders. During pregnancy, administer only when the potential benefits exceed the possible risks to mother and fetus.

Precautions: There have been infrequent reports of leukopenia and/or agranulocytosis and convulsive seizures. In epileptic patients, anticonvulsant medication should also be maintained. Prolonged treatment should be primarily in patients receiving larger than recommended doses, is characterized by diminution of visual acuity, brownish coloring of vision, and impairment of night vision; the possibility of its occurrence may be reduced by retaining within recommended dosage limits. Administer cautiously to patients participating in activities requiring complete mental alertness (e.g., driving), and in females than in males. Do not use epinephrine in treating drug-induced hypotension since phenothiazines may induce a reversed epinephrine effect on occasion. Daily doses in excess of 500 mg should be used only in severe neuropsychiatric conditions.

Adverse Reactions: Central Nervous System—Drowsiness, especially with large doses, early in treatment; frequently, pseudo-parkinsonism and other extrapyramidal symptoms; rarely, nocturnal

confusion, hyperactivity, lethargy, psychotic reactions, restlessness, and headache. **Autonomic Nervous System**—Dryness of mouth, blurred vision, constipation, nausea, vomiting, diarrhea, nasal stuffiness, and pallor. **Endocrine System**—Galactorrhea, breast engorgement, amenorrhea, inhibition of ejaculation, and peripheral edema. **Skin**—Dermatitis and skin eruptions of the urticarial type, photosensitivity. **Cardiovascular System**—ECG changes (see Cardiovascular Effects below). **Other**—Rare cases described as parotid swelling. The following reactions have occurred with phenothiazines and should be considered: **Autonomic Reactions**—Miosis, obstruction of lacrimal ducts, paralytic ileus, **Cutaneous Reactions**—Erythema, edematous dermatitis, contact dermatitis, thrombocytopenia, agranulocytosis, leukopenia, eosinophilia, thrombocytopenia, anemia, aplastic anemia, pancytopenia. **Allergic Reactions**—Fever, laryngeal edema, angioneurotic edema, asthma. **Hypotension**—Hypotension, hypotensive states. **Cardiovascular Effects**—Changes in terminal portion and inversion of T-wave, and appearance of a wave tentatively identified as a third T or a U wave have been observed with phenothiazines, including Mellaril (thioridazine); these appear to be reversible and due to altered relationship between these changes and significant disturbance of cardiac rhythm; several sudden and unexpected deaths apparently due to cardiac arrest have occurred while taking the drug. While proposed, periodic electrocardiogram are not regarded as positive. Hypotension rarely resulting in cardiac arrest. **Extrapyramidal Symptoms**—Akathisia, agitation, motor restlessness; dystonic reactions, trismus, torticollis, opisthotonos, oculogyric crises, tremor, muscular rigidity and akinesia. **Parasitic**

Tardive Dyskinesia—Persistent and sometimes irreversible tardive dyskinesia, characterized by rhythmic involuntary movements of the tongue, face, mouth, or jaw (e.g., protrusion of tongue, puffing of cheeks, puckering of mouth, chewing movements) and sometimes of extremities may occur on long-term therapy or after discontinuation of therapy, the risk being greater in elderly patients on high-dose therapy, especially females; if symptoms appear, discontinue all antipsychotic agents. Syndrome may be masked if treatment is instituted; dosage is increased, or antipsychotic agent is switched. Fine vermicular movements of tongue may be an early sign, and syndrome may not develop if medication is stopped at that time. **Endocrine Disturbances**—Menstrual irregularities, altered libido, gynecomaastia, lactation, weight gain, edema, false positive pregnancy tests. **Urinary Disturbances**—Retention, incontinence. **Others**—Hypertrophy; behavioral effects suggestive of a paradoxical reaction, including excitement, bizarre dreams, aggravation of psychosis, and toxic confusional states; following long-term treatment, a peculiar skin-eye syndrome marked by progressive pigmentation of skin or conjunctiva and/or accompanied by discoloration of exposed sclera and cornea; stellate or irregular opacities of anterior long and cornea; systemic lupus erythematosus-like syndrome. **Dosage:** Dosage must be individualized according to the degree of mental and emotional disturbance, and the smallest effective dosage should be determined for each patient. In adults with depressive neurosis the usual starting dosage is 25 mg b.i.d. and the dosage ranges from 10 mg b.i.d. to q.i.d. In mild or moderate cases to 60 mg b.i.d. or q.i.d. for more severely disturbed patients the total daily dose ranges from 20 mg to a maximum of 100 mg b.i.d. or q.i.d. **Contraindications:** Severe central nervous system depression; comatose states from any cause; hypersensitivity or hypotensive heart disease of extreme degree. **Warnings:** Administer cautiously to patients who have previously exhibited a hypersensitivity reaction (e.g., blood dyscrasias, jaundice) to phenothiazines. Phenothiazines are capable of potentiating central nervous system depressants (e.g., anesthetics, opiates, alcohol, etc.), as well as of blocking and potentiating inotropic agents; carefully consider benefits versus risks in less severe disorders. During pregnancy, administer only when the potential benefits exceed the possible risks to mother and fetus. **Precautions:** There have been infrequent reports of leukopenia and/or agranulocytosis and convulsive seizures. In epileptic patients, anticonvulsant medication should also be maintained. Prolonged treatment should be primarily in patients receiving larger than recommended doses, is characterized by diminution of visual acuity, brownish coloring of vision, and impairment of night vision; the possibility of its occurrence may be reduced by retaining within recommended dosage limits. Administer cautiously to patients participating in activities requiring complete mental alertness (e.g., driving), and in females than in males. Do not use epinephrine in treating drug-induced hypotension since phenothiazines may induce a reversed epinephrine effect on occasion. Daily doses in excess of 500 mg should be used only in severe neuropsychiatric conditions. **Adverse Reactions:** Central Nervous System—Drowsiness, especially with large doses, early in treatment; frequently, pseudo-parkinsonism and other extrapyramidal symptoms; rarely, nocturnal

Saturday, May 26, 1976

Pediatric Progress

...brief summaries of editorials or comments in current medical and scientific journals.

All Your Brains

"...one is born with all the brains he or she will ever have. In general, the reproductive capacity of cells or tissues is inversely related to their degree of specialization. Thus the squamous epithelial cells of the skin reproduce throughout life, though more slowly in old age, and an abrasion, when these cells are rubbed off, causes no concern. The skin will grow back. Cancer cells, having no function whatever, eventually die, by doing nothing but reproducing. On the other hand, the cells of the central nervous system, the most highly specialized in the body, have no reproductive power. Hence a brain cell lost at anytime after birth is lost forever. Therefore, be careful about head injuries..."

The present message, however, is directed to the fact that the brain at birth is cellularly complete and is, therefore, our most precious heritage. Throughout fetal life it must be fed a healthy circulation and carefully nourished during early childhood. These facts should provide a strong motivation for affording our children the best of prenatal and postnatal care and establishing dietary habits which will be maintained through life." (From "Cobb's Column," W. Montague Cobb, M.D., J. Natl. Med. Assn. 68:1, Jan., 1976)

Streptococcal Pharyngitis

"...optimal parenteral treatment of streptococcal pharyngitis in patients in the pediatric age group is probably best achieved by a single injection of 900,000 units of penicillin G benzathine and 300,000 units of penicillin G procaine. Although the procaine component does not hasten the resolution of signs and symptoms, when compared to the benzathine component alone, it does clear the throat of streptococci more rapidly and greatly decreases the incidence of severity of untoward reaction about the injection site. This preparation effects a cure rate equal to that of 1.2 million units of penicillin G benzathine alone and is significantly superior to that achieved with 600,000 units of the drug alone. This preparation fulfills the recommendation of the American Heart Association for the treatment of streptococcal pharyngitis in children and for the prevention of rheumatic fever." (James W. Bass, M.D., et al, JAMA 235:1112, Mar. 15, 1976)

Electric Pain Relief

Medical Tribune World Service

BANGALORE, INDIA—Application of a 100-microampere electric current to the skin can relieve pain associated with lumbago, spondylitis, periarthritis, osteoarthritis and other conditions, according to Dr. Mathew George, orthopedic surgeon at Hrnakulam General Hospital here.

Radiation Dose Lowered in Mammography

By FRANCES GOODNIGHT
Medical Tribune Staff

NEW YORK—Improvements in mammography techniques are now making it possible to screen for breast cancer with a radiation skin dose of 300 millirads (mR) or less, investigators reported here at the Third International Symposium on Detection and Prevention of Cancer.

Such dosage amounts to only a "small fraction" of the 1,000 to 4,000 or more mR produced by methods considered optimum just a short time ago, according to Dr. Philip Strax, medical director of New York's Guttman Institute.

Dr. Strax and other speakers at the symposium commented on recent publicity given to the possible ionizing radiation hazards of mammography, and expressed their belief that technological changes are greatly lessening potential risk.

"We must conclude," Dr. Strax said, "that there are now available mammography techniques that produce high quality films with minute mR doses that should allay all anxiety from repeated periodic mammograms as used in mass screening of apparently well women over the age of 35."

Rare Earth Screens

The introduction of rare earth screens is credited by Dr. Strax with facilitating the production of mammograms with "excellent resolution and contrast" at a low skin dose of radiation.

"In our hands, the use of an experimental Alpha type screen (made by the 3 M Company) with a matched green-sensitive double emulsion film has enabled us to reduce the dose to .2 to .3 R without any sacrifice of film quality perceptible to us," he said.

Investigators at the Guttman Institute are developing a device to permit automated screening with any screen-film system, at a resultant reduction in labor costs and film expenses.

Dr. Strax called mammography "of paramount importance" in the detection of early, localized breast cancer, and noted that 17% of the breast cancers detected at the institute in the years 1971-1974 would not have been found if this screening procedure had been omitted.

He emphasized, however, that palpation is the most important method, adding that its success is "directly related to the expertise of the one who palpates." Instruction in breast self-examination—given to all women screened at the institute—is essential for detection of "interval" cancer, he said.

What about thermography? In Dr. Strax's opinion, this should be used as part of the tandem approach to screening along with the interview, palpation and physical examination, and mammography. But its value lies in alerting the screening staff to the possibility of trouble, he said, since thermography does not detect or localize tumors.

New System

Another development in mammography resulting in low radiation dose was described at the symposium by investigators from the Los Angeles County-University of Southern California Medical Center.

The new system, called Xonics Electron Radiography, produces electrostatic images on a polyester sheet or receptor. Conventional x-ray film is not used and darkroom development is not necessary. The basic steps are generation of the latent electrostatic image in an imaging chamber, development of this latent image by an electrophoretic process into a visible image, and then the fixing of the image to yield a radiogram that can withstand normal handling.

Preliminary clinical trials with the process indicate that it can produce high-resolution, high-contrast mammograms at exposures to the patient of 50 to 80 mR, according to the Los Angeles team.

Authors of the report included Philip Muntz, Ph.D., and Drs. Evelyn Wilkinson and George Jacobson.

Improved Detection

The probability that better mammography techniques are leading to an increase in the number of cancers detected by such screening was suggested by Dr. William Pomerance, of the National Cancer Institute.

Dr. Pomerance evaluated results obtained so far from the 27 U.S. centers established as Breast Cancer Detection Demonstration Projects under the joint sponsorship of the American Cancer Society, the NCI, and the National Institutes of Health.

Summing up data on the efficiency of screening, he said it now appears that:

- The combination of mammography and physical examination detects 90% of extant breast cancer.
- Over 40% of that 90% are detected by mammography alone, with negative physical findings.
- Approximately three-fourths of the same 90% are free of axillary nodal involvement; and
- It is probable that more than three-fourths of cancers detected by mammography alone are free of involved nodes.

Dr. Pomerance noted that the percentage of cancers detected by mammography alone in the project centers is higher than the 33% figure reported in the mass screening study begun in 1963 by the Health Insurance Plan of Greater New York. Such an increase "is probably due to the considerable improvement in mammographic technique and interpretation that has occurred in the interim," he said.

Citing the reductions in radiation dosage already achieved, Dr. Pomerance expressed the hope that effective mammography screening can be performed with radiation skin doses below 150 mR per exposure. The potential of ultrasound for detection must continue to be investigated, he said, but at the present time "the combination of physical examination and mammography is an effective screen for the detection of early breast cancer."

Skin Cells Grown

Medical Tribune Report

CAMBRIDGE, MASS.—Human skin cells—previously resistant to attempts to grow them in the laboratory—can now be easily cultivated, using a technique developed by biologists here at the Massachusetts Institute of Technology.

The biologists, Professor Howard Green and former graduate student James G. Rheinwald (now a postdoctoral fellow) say that the technique, which includes culturing with irradiated fibroblasts, could be useful both in basic research and in medical research.

For example, skin cells grown in the laboratory could be used to study the effects of viruses such as the wart virus, to study the behavior of skin cells involved in diseases, and to test drugs.

It may also be possible to grow large quantities of a patient's skin to be used in skin grafts.



Sitting in on a discussion group for hospitalized children, now a standard procedure at Beth Israel Medical Center in New York, are Dr. Yehuda Nir, left, assistant chief of child psychiatry and Dr. Derris Coter, right. Isolated pediatric patients develop fears, anxieties and depression that may last for years. Pilot study showed that participants in group discussions take home fewer emotional scars after expressing their feelings in a therapeutic atmosphere.

Alcoholism Termed Soviet's 'Real Ideology'

By MICHAEL HERRING
Medical Tribune Staff

NEW YORK—There are now twice as many alcoholics in the Soviet Union as in the U.S., due in part to an astounding 500% increase in alcohol consumption since 1950, Dr. Boris Segal, former chief of a Soviet alcoholism program, said here.

"It is possible to say that it is not communism but rather drinking which is the real ideology of contemporary Soviet society," he recently told a meeting of the National Council on Alcoholism at New York University Medical Center.

In Russia, he said, the medical problems of dealing with alcoholism are compounded by strict censorship of

findings and the lingering persuasion of many officials that alcoholism is the "remnant of capitalism."

Dr. Segal, who is now research scientist at Harvard University's Russian Research Center, said much of his data was taken from studies he made in the Soviet Union from 1965 to 1972, only part of which were ever published.

"In the area of medical care, the main problem in both countries remains the insufficient number of qualified medical personnel, the insufficient intercommunication between medical, governmental, social, and educational institutions, and also the limited funds devoted to research and the search for new, effective methods of treatment," Dr. Segal said.

He also told the conference that:

- Between 1950 and 1973, US alcohol consumption rose 90%, while consumption in the U.S.S.R. soared 500%; both countries are among the world's ten heaviest consumers of alcohol.

- Soviets consume twice as much distilled spirits as Americans and the number of alcoholics is estimated at 18 million, twice as many as in America.

- Alcoholism in the U.S. causes about 50% of all fatal highway accidents, and 50% to 75% of all fatal accidents in the U.S.S.R.

- Drinking is heaviest among Soviet blue-collar workers and among the Irish and ghetto blacks here; the proportion of female to male alcoholics is higher in America.

- Urbanization, permissiveness, family disintegration, adolescent socialization, and feelings of victimization by society are common social causes for alcoholism in both countries.

- The growth of drinking in Russia is associated with economic depression and "the suppression of the personality, private initiative, and spiritual freedom."

In both countries, Dr. Segal said, measures to prevent alcoholism are inadequate. While antisocial drinking behavior is frowned upon more often in the Soviet media and in society, both governments have an active interest in the sale of alcohol, making preventive measures inconsistent and ineffective.

Both countries have insufficient youth programs and too few treatment modalities, though the multidisciplinary approach gets much lip service, he said.

Placidyl®[®] (ethchlorvynol capsules, N.F.) 500 & 750 mg.



Brief Summary

Indications:—Placidyl (ethchlorvynol) is indicated as short-term hypnotic therapy in the management of insomnia.

Contraindications:—Drug hypersensitivity and porphyria.

Warnings:—Not recommended during the first and second trimester of pregnancy, as the drug may produce CNS depression and transient withdrawal symptoms in the newborn. Caution patients of possible combined exaggerated effects with alcohol, barbiturates, tranquilizers or other CNS depressants. Exaggerated effects may result in blurring of vision, paralysis of accommodation and profound motor vehicle, operating machinery, or other hazardous operations requiring alertness after taking the drug. ADVISE PATIENTS WITH CAUTION TO PATIENTS WITH SUICIDAL TENDENCIES AND DO NOT PRESCRIBE LARGE QUANTITIES OF THE DRUG. Adjustment of the dosage of oral anticonvulsant therapy, during therapy, or after stopping therapy. This drug is not recommended for use in children. PLACIDYL HAS BEEN REPORTED FOR THE DEVELOPMENT OF PSYCHOLOGICAL AND PHYSICAL DEPENDENCY. INCREASED OF SEVERE WITHDRAWAL SYMPTOMS, INCLUDING CONVULSIONS AND DELIRIUM CLINICALLY SIMILAR TO THOSE SEEN WITH BARBITURATES, HAVE BEEN REPORTED IN PATIENTS TAKING REGULAR DOSES AS LOW AS 1000 mg. PER DAY SUDDENLY DISCONTINUED. PROLONGED ADMINISTRATION OF THE DRUG IS NOT RECOMMENDED. Addition-prone patients or those who are likely to increase dosages of the drug on their own initiative should be observed for evidence of early withdrawal or abstinence symptoms. Signs and symptoms which may indicate possible withdrawal include: anxiety, tremor, ataxia, slurring of speech, memory loss, perceptual distortions, irritability, agitation and delirium. Other signs and symptoms, not necessarily due to withdrawal and abstinence, may include anorexia, nausea or vomiting, weakness, dizziness, sweating, muscle twitching and weight loss. Abrupt discontinuance of Placidyl following prolonged overdosage may result in convulsions and delirium.

Precautions:—Toxic amblyopia has been reported with long-term continuous use of ethchlorvynol. Permanent visual defects have been observed, although amblyopia has improved after discontinuation of the drug. There have been reports of peripheral neuropathy associated with excessive ingestion of Placidyl. The onset of symptoms was concomitant with the increased ingestion of Placidyl, and reversal of symptoms closely followed the discontinuance of the drug. Drug dosages should be limited for elderly and debilitated patients to the smallest effective amount. If pain is present, this drug should only be given if insomnia persists after pain is controlled with analgesics. Caution is advised in prescribing the drug for patients who are being treated with either MAO inhibitors or antidepressants. Interaction of Placidyl and antihypertensives. Transient delirium has been reported with the combination of MAO inhibitors or antidepressants. Caution should be exercised if prescribed for patients receiving MAO inhibitors or antidepressants. Caution should be exercised in patients with impaired hepatic or renal function. Patients who respond unpredictably to barbiturates or alcohol, or who exhibit with such agents, may also react in this way to Placidyl. Rarely, patients may exhibit symptoms suggestive of an unusual susceptibility to the drug: weakness, excitement, tremors, or convulsive muscular marked hypotension. Transient glaucoma or acute angle closure glaucoma has been reported in patients receiving Placidyl.

Adverse Reactions:—Hypotension, nausea or vomiting, gastric upset, ataxia, blurring of vision, dizziness, facial numbness, and allergic reactions, typified by urticaria, have been reported following Placidyl administration. Mild "hangover" and symptoms of mild excitation have occurred in some patients. There have been rare reports of chills, shivering, and rigors occurring in patients taking ethchlorvynol. A few cases of thrombocytopenia have been reported in patients receiving ethchlorvynol.

ABBOTT LABORATORIES
North Chicago, Illinois 60064

It must have been some twenty-five year old kid that wrote, "life begins at 40"

Some beginning. A bald spot that keeps getting bigger, a dead end job, and last week a neighbor younger than he is had a heart attack. Night after night, the collective realities of middle age push him to near-panic.

His insomnia, like the majority of insomnia cases, is secondary to psychologic disturbance.

This patient needs help. And he needs sleep. Until he can be counseled to deal with his fears, Placidyl can help ease the effects of insomnia.

For over 19 years physicians have found Placidyl to be an effective agent in the short-term management of insomnia. And, an effective alternative to the barbiturates.

If time is the criterion to inspire your confidence... you can rest assured with Placidyl.

J. Kales, A. Kales, J.D. Sleep Disorders, *The New England Journal of Medicine*, 290:9, 487-93, Feb 28, 1974.

Indicated as short-term hypnotic therapy in the management of insomnia.

Placidyl®[®]
(ethchlorvynol capsules,
N.F.) 500 & 750 mg.

ABBOTT LABORATORIES
North Chicago, Illinois 60064
See opposite page for Brief Summary.

Respiratory Aid Improves Survival of High Risk Infants

By JULIAN DeVRIES
Special Tribune Correspondent

Intermittent mandatory respiration is improving the survival rate of high risk, low birth weight infants, Dr. John S. McDonald, Assistant Professor of Obstetrics and Gynecology at Los Angeles County-University of Southern California Medical Center, reported here.

While early obstetric care, careful electronic management and improved neonatal care have played important roles in the reduction of neonatal mortality, the introduction of new aspects of respiratory care has greatly enhanced the physician's ability to maintain viable support for small, high risk infants, he told the 50th Congress of the International Anesthesia Research Society here.

"We are impressed," Dr. McDonald said, "that the institution of more intensive respiratory management for support of both ventilation and oxygenation problems has significantly improved survival in the 1,000-2,000 g neonates."

First step in establishing respiratory assistance for the low birth weight neonate, he said, is to determine baseline blood gas volumes via an umbilical artery catheter. If the initial values

show either a primary oxygenation or ventilation problem, or both, which were not relieved by nontracheal tube management, or if it is immediately apparent that tube management is indicated, a No. 2.5-4.0 mm uniform diameter endotracheal tube is inserted orally following pre-oxygenation and mask and bag ventilation. Accurate tube placement is confirmed by X-ray. The catheter tip, Dr. McDonald said, should lie above the carina.

Following intubation, the infant is placed in a Baby Bird or Bourns ventilator. When this no longer is required the infant is managed with supplemental oxygen or continuous positive airway pressure (CPAP) or both, as needed until extubation becomes possible.

Preliminary Review

A preliminary review of the modality's statistics for 1975, Dr. McDonald said, reveal that survival rates in the less than 1,500 g neonate and the less than 2,000 g infant may be as high as 59% and 69% respectively.

Dr. McDonald's preliminary 1975 figures indicate a considerable improvement over his statistics covering the period from July 1973 to June 1974. During that year, he said, of 27 hospital admissions of 1,000 g or less ne-



High risk, low birth weight infants are placed on a Baby Bird (pictured) or Bourns ventilator as part of Dr. McDonald's improved modality of management.

ates given intermittent mandatory respiration, 11 survived and 16 died, giving a survival rate of 41%.

Of 63 neonates in the 1,500 g or under category, Dr. McDonald's figures show, there were 31 survivors with 32 deaths for a survival rate of 49%.

Among 44 neonates weighing 2,000 g or less, 19 lived and 21 died, for a survival rate of 43%.

However, among 82 neonates whose birth weight was 2,000 g, or more, 66 survived and only 16 died, giving a survival rate of 80%.

"The original concept of a high risk infant," McDonald said, "was simply the premature, originally described in 1919. While the original criterion of 2,500 g was useful as a division between 'maturity' and 'prematurity' and allowed early useful comparative data,

it also revealed the need for a special consideration for a heretofore unrecognized phenomenon—the small for date neonate.

"In addition, important steps have been made in the cognizance of the two involved specialties, obstetrics and pediatrics, that perinatal mortality can be substantially reduced by close communication and co-ordination of high risk pregnancies and the institution of supportive life maintenance systems for the high risk neonate.

"Thus, in our particular setting, it would appear that such management has substantially enhanced neonatal survival in this high risk population. To what degree is, of course, unknown since many other improved modalities of management were instituted around the same time."

Erythromycin in Serum Higher If Given After Meals

By HARRIET PAGE
Special Tribune Correspondent

STATTLE, WASH.—Bioavailability studies with sick children given erythromycin succinate indicate that they handle it pretty much as adults do, attaining higher serum levels when the drug is given after a meal than after fasting.

Dr. Terrence C. Coyne, who described the study here to the American Society for Clinical Pharmacology and Therapeutics, said this does not mean that the drug is therapeutically inadequate when given on an empty stomach, since experience and published data support its efficacy given that way.

But, said Dr. Coyne, who is associate director of clinical research for Abbott Laboratories in North Chicago, Ill., the study does seem to show that dosage extrapolation from the adult dose based on weight "is appropriate, and does result in adequate serum levels in children."

Dr. Coyne told MEDICAL TRIBUNE that the study demonstrates that bioavailability studies in children are possible, and do yield valuable data, even though a crossover design cannot be followed that would reduce subject-to-subject variation. And while results cannot be quantitatively compared to studies with healthy volunteers, valid extrapolation can be seen.

The investigator noted that because of ethical considerations, most, if not all, bioavailability data is obtained from normal healthy adult subjects.

As a result, bioavailability information in the young pediatric population is rarely available, thus regulatory agencies and clinicians have limited

data on which to base an objective decision for determining appropriate and effective dosage or approving usage in the very young age groups. Typically, the pediatric dose is extrapolated from the adult dose on either an age or weight basis," Dr. Coyne said.

The study group consisted of 27 children, aged six months to six years, who required antibiotic therapy for an infection that would be treatable with erythromycin. They were admitted to

the hospital and randomly assigned to one of the two groups.

The 13 patients assigned to the other group received the same meal at the end of the fast. A half-hour later a zero-time blood sample was drawn, followed by drug administration.

The drug was given to all patients, Dr. Coyne said, on approximately a 40 to 50 mg/Kg/day basis, as recommended by the product label.


Mean serum levels of the patients in

the fasting group peaked at 1.31 micrograms/ml one hour after dosing. Dr. Coyne said, while levels in the non-fasting group rose almost twice as high, to 2.60 micrograms/ml, one-and-a-half hours after dosing.

The same drug was given to 23 healthy adults in a single 400 mg oral dose under both fasting and non-fasting conditions, in a randomized two-way crossover design. As with the children, the non-fasting dose regimen in the adults produced higher levels than the fasting regimen.

Wrist Implant Restores Function

A NEW TYPE OF ARTIFICIAL WRIST JOINT, which permits palmar flexion and extension and radial-ulnar deviation, has been successfully implanted in over 20 patients, says orthopedic surgeon Robert G. Voiz, of the University of Arizona Medical Center, Tucson. Made of plastic and metal, the device has two interlocking parts which permit motion in only two planes, as does the anatomical wrist. Unlike ball and socket joints, the new device does not allow unnatural rotation through the wrist.



Device is inserted (photo at far left) so that proximal end fits into radius and proximal end into second and third metacarpals. Knurled surfaces strengthen bone-cement interface. Implant in right wrist let organist (above, left) resume career cut short by fall; Woman (above, right), crippled by rheumatoid arthritis, can now open doors.

"Let me tell you about the medicine I'm going to prescribe."

TALKING OVER VALIUM®(diazepam) THERAPY WITH YOUR ANXIOUS PATIENT.



And it's also good for him to realize that he will be taking Valium only as long as he needs it.

Your expressed confidence in the medication prescribed, and the positive atmosphere in which therapy is given and accepted, work to the patient's advantage.

A patient often benefits by a greater understanding of his treatment program. You may find it helpful to make your patient aware that the purpose of therapy with Valium is to help reduce discomforting and disabling symptoms of excessive psychic tension and anxiety. It is beneficial for him to understand that much of his tension and anxiety can be relieved by your reassurance and counseling, and that these measures can do more than anything else to help him cope with

his basic problems. The patient is reassured in knowing he can expect his medication to help him avoid feeling overwhelmed by his symptoms.

Selection of a dosage regimen is an important consideration when Valium (diazepam) is prescribed, and dosage should be individualized to achieve maximum beneficial effect. If the patient understands clearly when and how much to take, and if he knows why it's to his benefit to follow the regimen closely, the chances are better that he will take the medication precisely as directed. That should help avoid missed doses and discourage taking too much or too little medication — all of which can have an undesirable effect on the management of the patient's condition.

"It's important that you follow my directions closely."

"I'll see you again the week after next and we'll see how you're making out."

Your patient is often likely to feel reassured when you talk about seeing him again to check his progress. A planned visit evidences your continued interest and affords the patient an opportunity to report improvement he has made and to relate whatever continuing or additional difficulties he may be experiencing. It's also a chance for him to describe his response to therapy with Valium.

During follow-up visits, as your patient talks about his medication and about its effects on his symptoms, he will provide the kind of information that will be of great help in evaluating total therapy, adjusting the dosage of Valium, or discontinuing the medication entirely if that seems indicated.

Valium® (diazepam) [®]

2-mg, 5-mg, 10-mg scored tablets [®]

for individualized treatment of psychic tension



Please see the following page for a summary of product information.



Valium® (diazepam)

2-mg, 5-mg, 10-mg scored tablets

Prompt, effective action. Valium (diazepam) works rapidly to relieve pronounced psychic tension in patients overreacting to stress and in psychoneurotic patients.

Before prescribing, please consult complete product information, a summary of which follows:

Indications: Tension and anxiety states; somatic complaints which are concomitants of emotional factors; psychoneurotic states manifested by tension, anxiety, apprehension, fatigue, depressive symptoms or agitation; symptomatic relief of acute agitation, tremor, delirium tremens and hallucinosis due to acute alcohol withdrawal; adjunctively in skeletal muscle spasm due to reflex spasm to local pathology; spasticity caused by upper motor neuron disorders; athetosis; stiff-man syndrome; convulsive disorders (not for sole therapy).

Contraindicated: Known hypersensitivity to the drug. Children under 6 months of age. Acute narrow angle glaucoma; may be used in patients with open angle glaucoma who are receiving appropriate therapy.

Warnings: Not of value in psychotic patients. Caution against hazardous occupations requiring complete mental alertness. When used adjunctively in convulsive disorders, possibility of increase in frequency and/or severity of grand mal seizures may require increased dosage of standard anticonvulsant medication; abrupt withdrawal may be associated with temporary increase in frequency and/or severity of seizures. Advise against simultaneous ingestion of alcohol and other CNS depressants. Withdrawal symptoms (similar to those with barbiturates and alcohol) have occurred following abrupt discontinuance (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating). Keep addiction-prone individuals under careful surveillance because of their predisposition to habituation and dependence. In pregnancy, lactation or women of childbearing age, weigh potential benefit against possible hazard.

Precautions: If combined with other psychotropics or anticonvulsants, consider carefully pharmacology of agents employed; drugs such as phenothiazines, narcotics, barbiturates, MAO inhibitors and other anti-

depressants may potentiate its action. Usual precautions indicated in patients severely depressed, or with latent depression, or with suicidal tendencies. Observe usual precautions in impaired renal or hepatic function. Limit dosage to smallest effective amount in elderly and debilitated to preclude ataxia or oversedation.

Dosage flexibility. Scored Valium 2-, 5-, and 10-mg tablets give you dosage flexibility no tranquilizer capsule can match.

Side Effects: Drowsiness, confusion, diplopia, hypotension, changes in libido, nausea, fatigue, depression, dysarthria, jaundice, skin rash, ataxia, constipation, headache, incontinence, changes in salivation, slurred speech, tremor, vertigo, urinary retention, blurred vision. Paradoxical reactions such as acute hyperexcited states, anxiety, hallucinations, increased muscle spasticity, insomnia, rage, sleep disturbances, stimulation have been reported; should these occur, discontinue drug. Isolated reports of neutropenia, jaundice; periodic blood counts and liver function tests advisable during long-term therapy.

Dosage: Individualize for maximum beneficial effect. **Adults:** Tension, anxiety and psychoneurotic states, 2 to 10 mg b.i.d. to q.i.d.; alcoholism, 10 mg t.i.d. or q.i.d. in first 24 hours, then 5 mg t.i.d. or q.i.d. as needed; adjunctively in skeletal muscle spasm, 2 to 10 mg t.i.d. or q.i.d.; adjunctively in convulsive disorders, 2 to 10 mg b.i.d. to q.i.d. **Geriatric or debilitated patients:** 2 to 2½ mg, 1 or 2 times daily initially, increasing as needed and tolerated. (See Precautions.) **Children:** 1 to 2½ mg t.i.d. or q.i.d. initially, increasing as needed and tolerated (not for use under 6 months).

Supplied: Valium® (diazepam) Tablets, 2 mg, 5 mg and 10 mg—bottles of 100 and 500; Tel-B-Dose® packages of 100, available in trays of 4 reverse-numbered boxes of 25, and in boxes containing 10 strips of 10; Prescription Paks of 50, available singly and in trays of 10.



Roche Laboratories
Division of Hoffmann-La Roche Inc.
Nutley, New Jersey 07110

Wednesday, May 26, 1976

MEDICAL TRIBUNE

11

The Only Independent Weekly Medical Newspaper in the U.S.

Medical Tribune

and Medical News
Published by Medical Tribune, Inc.

The Bad News

A Sad Day for American Inventiveness and Ingenuity

WITH THE INEVITABILITY of a Greek tragedy, the United States is moving towards legislation which will establish wide ranging government control over medical devices. What is intended as enlightened legislation may be a mixed blessing. The new devices bill is being sponsored, among others, by Congressman Paul Rogers who for so long has been a balanced and effective spokesman in Congress for positive aspects of health care. There is no doubt that Congressman Rogers is reacting to a number of serious abuses in the area of devices—in poor design and poor manufacturing practices. We are concerned as to how many babies are being thrown out with the dirty bath water.

Regulations do exist to control fraudulent devices and there are ways other than proliferating extensive legislation to control defective design and bad manufacturing practices, and to do so without eviscerating the guts of what made America the leader in the field of medical devices. We have been informed by knowledgeable physicians that "At present, the Food and Drug Administration exerts control over the medical device industry through the Bureau of Medical Devices and Diagnostic Products, which already employs over 200 people. The existing Food, Drug and Cosmetic Act empowers the Agency to regulate any medical device that is adulterated or misbranded. The actions available to the Agency for violations of that law include seizure, injunction, criminal prosecution and imprisonment of persons responsible."

The medical device industry is also forcefully and effectively regulated by the medical liability climate in this country."

Many specialists in this field are fearful of bureaucratic red tape. They believe that if the procedures currently applicable to drugs had been applicable to devices, many, if not most, that are currently considered among the miracles of modern medicine could have died aborning or delivered only after tragic and unnecessarily long development. Could valve prostheses ever have come to fulfillment and, if so, with how many years of delay under the prospective new government regulations? They further believe it is not beyond the realm of possibility that as much as \$1 billion may be added annually to the cost of medical care in this country by this measure.

Sad to say, the day when the brilliant, independent young medical device inventor and innovator could carry his creation through from concept to wide clinical use may be gone. Yet such individuals pioneered the field and gave the impetus to American leadership in the development of medical devices. The flood of regulations and the inevitable bureaucratic time and money-consuming red tape that will ensue can only be coped with and the costs met by a few very large, financially powerful organizations.

It is a sad day for the individual American pioneer with inventiveness and ingenuity and initiative in the field of medical devices.

... And the Good News

A Few Signs that a Modicum of Good Sense May Prevail

FROM A POSITIVE ASPECT, as the device legislation proceeded through Congress, a number of important safeguards for research and progress were built into the legislation. While individual inventors may not be able to carry their devices from creation through to the marketplace, there will be fewer of the maddening restrictions which exist in respect to drug research. Clinical investigators seeking to study new devices will not be forced through the laborious approval of protocols by an already overloaded Washington bureaucracy. Responsible researchers will be able to carry on clinical investigations with device research protocols approved by their institutional or local hospital committees.

As to "informed consent," the House version introduced a tiny modicum of flexibility, avoiding the "setting

into concrete" of a mass of requirements of questionable value. "Informed consent" has been propagandized and converted into "code words" that have become the proprietary slogans of some strident, self-appointed crusaders. As clear as it is that "informed consent" constitutes a valid and vital area of ethical and moral, social and scientific concern, it is equally evident that its senseless and insensitive application "across the board" by legislative or regulatory mandate can frighten patients from needed life-saving measures and "protect" much pathology from corrective, scientific intervention.

Furthermore, patients abroad will not be kept from the fruits of American medical device research by regulations which, regardless of whether they make sense or nonsense here, may not



"You were racing the man in Room 207 again and hit the wall.
... Stop saying you hit a pothole."

© 1976, Medical Tribune, Inc.

be applicable in their countries. Other countries will not be forced to accept American imposed "standards" without relevance to local situations or in the face of different but valid points of view from their own experts. The export of American devices can be undertaken as long as they are not fraudulent, neither adulterated nor misbranded, and meet the standards or legal specifications of the countries which desire to acquire them.

These aspects of the devices bill are encouraging signs that Congress can

legislate "with its feet on the ground," that the scientific community, if it properly states a valid position, may still be heard and responded to by responsible legislators. One can only hope that those positive precedents which have been set in our device legislation may also be applied to drugs—in the interests of research, patients and the public health. A.M.S.

*Quotation from letter to A.M.S. from Shirley R. Andersen, M.D., H. W. Andersen Products, Inc., 45 East Main St., Oyster Bay, N.Y. 11771. Jan. 31, 1976.

LETTERS TO TRIBUNE

Thermography's Usefulness

MEDICAL TRIBUNE (Feb. 25) published an article stating thermography is not reliable in screening for breast cancer, citing two different studies, one from the program for cancer detection in centers in Milwaukee and another from Jefferson University in Philadelphia. In both studies, thermography has been given a very low grade of accuracy.

It is our experience that thermography deserves a better place in breast screening. We have been doing thermography for over a year and one-half. This is combined with physical examination, and selective mammography in cases of abnormal thermograms.

In 1500 consecutive cases of gynecological patients over the age of 35, we have been able to detect 12 cases, five of them were occult cancer. In all the 12 patients with cancer, only one had a false negative thermogram and this was Page's disease of the nipple. In this particular case, the surgeon did not perform a mammogram and biopsy was done on a physical finding. This was the only case in which a mammogram was not done. In all the other cases, a mammogram was done. In one case which the thermogram was reported as abnormal, the physical examination was normal, the mammogram was reported abnormal and the mammograms on two different occasions were reported normal. This patient had advanced carcinoma and 15 out of 18

lymph nodes were positive.


Our protocol is to examine the patients and do a thermogram. If the thermogram is reported abnormal, the patient is submitted to a mammogram. The patient is sent to a surgeon only if the mammogram or the physical examination is abnormal. If only the thermogram is abnormal no biopsy is done, but the patient is re-examined more frequently.

Our results show that 23.3% have a "false positive" thermogram. Mammograms have been done in these cases. Only 19% of the mammograms were reported normal. The rest, or 81% of the mammograms done on the "false positive" basis, were reported to have various non-malignant breast diseases.

In our screening program, 47 patients out of 1500 underwent breast biopsies. Of them, 26% have proven to be cancer, with five being occult cancer. In our hospital, when thermography and mammography were not done before biopsy, only 10% of those patients submitted to breast biopsies had malignancies.

Since our first 1500 cases, we have found another occult cancer. Several other patients are pending biopsies of the breast at present. Our patients come from the private practice of two gynecologists, with a few referrals from other doctors in the area.

RAMON L. AMOR, M.D.
W. JAMES BAGGS, M.D.
Newport News, Va.



The problem of hypokalemia had a distasteful solution...

until now

matrix with a mission
...for the treatment of hypokalemia
...for the prevention of hypokalemia when
dietary intake of K is inadequate

Slow-K®

(potassium chloride)

slow-release tablets 8mEq



The mission: to deliver K patients can take

The Slow-K wax matrix is intended to provide a controlled release of potassium to minimize the likelihood of high local concentrations of potassium within the gastrointestinal tract. Comparison studies¹⁻³ show Slow-K to be far more palatable and convenient than liquid KCl. Furthermore, Slow-K caused much less nausea, heartburn and diarrhea (occurrence of abdominal cramping was comparable). Also, no evidence of GI bleeding was detected when Slow-K was administered daily for 14 days to 30 male volunteers.

The mission: to deliver K patients will take

The problem of patient compliance posed by the unpleasant taste and aftertaste of liquid potassium supplements is not a factor one need be concerned with when prescribing sugar-coated Slow-K tablets. For when compared to liquid KCl preparations¹⁻³ or to a potassium gluconate elixir,^{4,5} Slow-K proved far more palatable—as well as more convenient and more acceptable—to the great majority of patients.

The chloride anion

Slow-K provides the chloride anion which, combined with K⁺, is essential for restoring normal acid-base and potassium balance in patients with hypokalemic alkalosis.⁶

Dependable potassium supplementation

Slow-K maintained normal serum K levels as effectively as liquid KCl preparations^{2,3} and as a potassium gluconate elixir,⁴ according to open-label crossover studies.^{2,3,5} And Slow-K has over 10 years' worldwide clinical experience, with over 4 billion tablets dispensed.*

*Potassium chloride tablets have produced small and/or ulcerative lesions of the small bowel and duodenum. Similar lesions have also been reported with liquid K supplements. A few cases reported with wax-matrix tablets have also been reported. The frequency of these lesions, however, is much less with wax-matrix tablets (less than 1 per 100,000 patient-years) than with enteric-coated KCl tablets (40-50 per 100,000 patient-years). While solid forms of K supplementation are contraindicated in any patient in whom there is a cause for arrest or delay in tablet passage through the GI tract.

References
1. Division of Medical Research Department, CIBA Pharmaceutical Company, Summit, New Jersey.
2. Hays EL. Controlled-release potassium supplementation. *Curr Ther Res* 16:754-761, 1974.
3. Cooper H. Potassium supplementation during diuretic therapy. *Curr Ther Res* 17:559-563, 1975.
4. Hays EL, Cavallera MS, Dautman WG, Arnold JD, et al. Absence of gastrointestinal bleeding with controlled-release potassium chloride tablets. *Ann Pharmacol Ther* 16:585-590, 1974.
5. Hutchinson JC. Clinical evaluation of a new wax-matrix potassium chloride supplement. *J Clin Pharmacol* 14:524-529, 1974.
6. Lawrence JP, Berkman PM, Lawrence DR, et al. The clinical role of chloride in the correction of hypokalemic alkalosis in man. *Am J Med Sci* 172:165-166, 1966.

Slow-K®
(potassium chloride)

INDICATIONS
Treatment of potassium depletion in patients with hypokalemia and metabolic alkalosis, and prevention of potassium depletion during treatment of digitalis intoxication. During therapy serum potassium levels should be monitored and laboratory effects.

Contraindications
Prevention of potassium depletion when digitalis administration is inadequate. Prophylactic administration of potassium ion may be indicated in patients receiving digitalis and in patients with congestive heart failure, myocardial infarction with arrhythmias, paroxysmal nocturnal dyspnea, pulmonary edema, and certain diarrheal states.

CONTRAINDICATIONS
In patients with hyperkalemia, since a further increase in serum potassium concentration in such patients can produce cardiac arrest. Hyperkalemia may complicate any of the following conditions: chronic renal failure, systemic acidosis such as diabetic acidosis, acute dehydration, extensive tissue breakdown as in severe burns, adrenal insufficiency, or the administration of a potassium-sparing diuretic (eg, spironolactone, triamterene).
Wax-matrix potassium chloride preparations have produced esophageal ulceration in certain cardiac patients with esophageal compression due to enlarged left atrium.
All solid dosage forms of potassium supplements are contraindicated in any patient in whom there is a cause for arrest or delay in tablet passage through the GI tract. In these instances, potassium supplementation should be with a liquid preparation.

WARNINGS
In patients with impaired mechanisms for excreting potassium, administration of potassium salts can produce hyperkalemia and cardiac arrest. This occurs most commonly in patients given potassium intravenously but may also occur when given orally. Potentially fatal hyperkalemia can develop rapidly and be symptomatic. Use of potassium salts in patients with chronic renal disease, or any other condition which impairs potassium excretion, requires particularly careful monitoring of the serum potassium concentration and appropriate dosage adjustment.
Hypokalemia should not be treated by the concomitant administration of potassium salts and a potassium-sparing diuretic (eg, spironolactone or triamterene), since the simultaneous administration of these agents can produce severe hyperkalemia.

Potassium chloride tablets have produced small and/or ulcerative lesions of the small intestine and duodenum. These lesions are caused by a high localized concentration of potassium ion in the region of a rapidly dissolving tablet, which injures the bowel wall and thereby produces obstruction, hemorrhage, or perforation. Slow-K tablets, being formulated to provide a controlled rate of release of potassium chloride, thus minimize the possibility of a high local concentration of potassium ion near the bowel wall. While the reported frequency of small bowel lesions is much less with wax-matrix tablets (less than one per 100,000 patient-years) than with enteric-coated potassium chloride tablets (40-50 per 100,000 patient-years), a few cases associated with wax-matrix tablets have been reported. These data are from foreign marketing experience. Slow-K should be discontinued immediately and the possibility of bowel obstruction or perforation considered if severe vomiting, abdominal pain, distention, or gastrointestinal bleeding occurs.
Hypokalemia in patients with metabolic alkalosis should be treated with an alkalinizing potassium salt such as potassium bicarbonate, potassium citrate, or potassium acetate.

PRECAUTIONS
Potassium depletion is ordinarily diagnosed by clinical history suggesting some cause for potassium depletion. In interpreting the serum potassium level, the physician should bear in mind that acute alkalosis per se can produce hypokalemia in the absence of a deficit in total body potassium, while acute acidosis per se can increase the serum potassium concentration in the normal range even in the presence of a reduced total body potassium.
Treatment of potassium depletion, particularly

In presence of cardiac disease, renal disease, or pulmonary disease, requires careful attention to acid-base balance and appropriate monitoring of serum electrolytes, electrocardiogram, and clinical status of patient.

ADVERSE REACTIONS
Most common to oral potassium salts: nausea, vomiting, abdominal discomfort, and diarrhea. These symptoms are due to irritation of the gastrointestinal tract and are best managed by diluting the preparation (further, taking the dose with meals, or reducing the dose).
Most severe adverse effects: hyperkalemia and gastrointestinal obstruction, bleeding, or perforation.

DOSEAGE AND ADMINISTRATION
Usual dietary intake of potassium by the average adult is 40 to 60 mEq per day. Potassium depletion sufficient to cause hypokalemia usually requires loss of 200 or more mEq of potassium from the total body store.
Dosage must be adjusted to the individual needs of each patient but is typically in the range of 20 mEq per day for prevention of hypokalemia to 40-100 mEq per day or more for treatment of potassium depletion.

HOW SUPPLIED
Tablets (sugar-coated, sugar-coated), each containing 800 mg (8 mEq) potassium chloride; bottles of 100 and 1000.

Consult complete literature before prescribing.
CIBA Pharmaceutical Company
Division of CIBA-GEIGY Corporation
Summit, New Jersey 07901.

C I B A

Diabetes Assn. Says Principal Goal Of Therapy Is Blood Sugar Control

Continued from page 1

That evidence, the association said, now "places the burden of proof upon those who maintain that diabetes control is without effect."

"Current clinical and experimental data clearly demonstrate that optimal regulation of glucose levels should be achieved in the treatment of diabetes, particularly in young and middle-aged individuals who are at greatest risk of developing the microvascular complications," the ADA declared.

The statement was signed by Dr. George Cahill, Jr., ADA president and director of research at the Joslin Clinic; Dr. Donnell D. Etzweiler, President-Elect and Director of the Diabetes Educational Center, Minneapolis; and Dr. Norbert Freinkel, Vice President, ADA Professional Section, and Kettering Professor of Medicine, Northwestern University.

Dr. Cahill told MEDICAL TRIBUNE that the action was "unprecedented," but added that "somewhere, we felt, a position had to be taken" based on the best available evidence.

Better Correction Needed

In the statement, the ADA acknowledged that "current methods of therapy are only partly effective at best" and urged that "a high priority should be assigned to the development of more physiologic insulin delivery systems or to approaches to the correction of the deficient insulin-producing mechanism itself."

But in the absence of such optimal solutions, the organization observed,

good diabetic management in the present state of knowledge suggests that what is "most important is a commitment to the view that better 'control,' when achievable, is beneficial."

Decreased Nephropathy

"For almost 50 years, since insulin therapy was initiated, proponents of 'rigid,' 'tight,' or 'chemical' control quoted retrospective evidence of decreased or delayed nephropathy or retinopathy as glucose levels are brought by therapy towards the normal range," the ADA said. "Opponents of this hypothesis pointed to the problems of complications in many of the supposedly better-controlled patients, to the emotional and socio-economic conflicts which often resulted from the demands of rigorous control, to the frequent difficulties with hypoglycemic reactions and, recently, to the University Group Diabetes Project."

The UGDP study, however, did not settle the controversy, the association noted, since the five forms of therapy employed "failed to demonstrate any effect upon microvascular lesions." The reason, the ADA said, was that "the middle-aged or older subjects studied exhibited only minimal initial hyperglycemia, and the reduction in blood glucose was small, so the results are not directly pertinent to the relationship between glucose levels and microvascular lesions."

A new picture began emerging, however, with a variety of recent studies that shifted the preponderance of evidence in favor of control. The ADA statement cited data from studies in a wide range of animals, including primates, showing that "reduction of hyperglycemia by insulin therapy, by transplantation of insulin-producing tissues, or by other means, prevents or minimizes formation of diabetic-like lesions in eye, kidney and nerve."

Hemoglobin Altered

Further, biochemical studies "have shown persistent hyperglycemia to be associated with accumulation of sorbitol in nerve, eye and vascular tissue and with alterations in vascular basement membrane," the statement continued. "Most recently, even hemoglobin has been found altered in man and experimental animals in the presence of persistent and prolonged hyperglycemia."

And, finally, the ADA said, "In a small but prospective study of randomly assigned patients, just reported from Paris, enthusiastically well-controlled diabetic subjects showed less retinopathy. Thus, the contention that the microvascular complications occur independently of the hyperglycemia and insulin deficiency and that control of the metabolic events is not a factor in their progress does not appear tenable any longer."

The ADA policy statement culminates some six months of behind-the-scenes discussion among the organization's scientific and lay leadership. But the impulse that prompted the discussion, an ADA spokesman said, goes back much earlier, to a proposal two

years ago by Drs. Karl E. Sussman, of the University of Colorado, and Robert Metz, of the Mason Clinic, Seattle, who contended that the time had come for the ADA to develop minimal criteria for the treatment of juvenile and adult diabetes.

Dr. Cahill stressed, however, that before treatment criteria could be developed, a concept and philosophy of control had to be established. He therefore drafted last year a statement on control that was submitted for review to 28 investigators and clinicians and some lay leaders in three major ADA committees—the Committee for Research and Scientific Affairs, the Committee on Materials and Therapeutic Agents, and the Committee on Professional Activities.

It was Dr. Cahill's draft that formed the basis for the policy stand ultimately adopted by the ADA.

In the interview, he said the ADA's principal motive for preparing the policy statement was to "upgrade medical practice" by outlining what is believed to be the best available information on the subject of control.

"Some people feel that the issue has not been scientifically resolved," he commented. "But a controlled study of this nature is almost impossible to conduct. One has to agree, in a way, with those diabetologists who contend that the case for blood sugar control lacks truly hard scientific evidence."

Nevertheless, he said, "There is now sufficient data, including well-designed prospective studies, to suggest that the better you take care of the diabetic's blood sugar, the more beneficial the results."

Infrared Helps Control Burn Hypermetabolism

Medical Tribune Report

SAN ANTONIO—A unique but simple method for controlling hypermetabolism in patients with extensive burns was reported here by Dr. Gösta Arturson, director of the burn center at University Hospital, Uppsala, Sweden.

Dr. Arturson's patients control their own heat supply by turning on infrared heaters placed over the bed.

"Whether hypermetabolism is caused by the patient's being externally cold or internally warm is a continuing controversy among burn specialists," said Dr. Arturson. "But no hypermetabolism was found in burn patients when they controlled their own heat supply."

Burn specialists agree that the serious problem of heat loss in burn patients is a result of increased evaporation, radiation, and convection. There are several ways to reduce the loss but it has not been possible to lower the energy expenditure to a normal level for the patient's actual core temperature.

"The reason for this," said Dr. Arturson, "may be that the heat loss is so large that no treatment applied decreases the heat loss enough or transfers an adequate amount of heat to the patient for complete elimination of the hypermetabolism."

Advantages of infrared heaters include low expense, ambient air temperature can be kept normal, and decreased patient need for I.V. or oral caloric intake, Dr. Arturson said.

Tribune Economic Analysis



Market Turning In Favor of The Farmers?

By ELIOT JANEWAY
Consulting Economist

An angry new confrontation is brewing between America's farmers and their customers. At the worst of the 1973 inflation fever rash, the food-consuming public staged a boycott against food prices. It worked. The farmers have been hurt, and they are waiting for the day when they can get their own back.

Despite Department of Agriculture propaganda threatening America's farmers with burial under mountains of new grain surpluses, they are sensing that the market is turning back in their favor. When it does, food prices will shoot up again.

The pressure for higher farm prices is rising along with the market prices for good farm land and the astronomical cost of investment in maximizing yields per acre. In fact, farm production now takes so much capital that it is sharing the need of industry for higher prices and higher production. Neither one will offset the other, as in the past.

The fusion of uneconomically high fuel prices and economically high food prices will quickly dispel the illusion that anything was done about inflation while America was appeasing the world oil cartel and shrugging off the distress of her farmers.

Ask Janeway

I'm a 41-year-old pharmacist in the 39% bracket. I have approximately \$100,000 invested in mutual funds, common stocks, and bonds, including tax-exempts. I am particularly concerned about tax-deferred annuities. How safe are they? What is their cost-effectiveness relative to alternative investments?

Arizona Pharmacist

Safety is not the question to worry about with annuities. All the insurance companies selling them are safe. The question is whether they represent an economic use of money. As my handbook *You and Your Money* explains, they are bets on life expectancies. The buyers are paid back mainly in their own money. The only way they come out ahead is by living long enough to start getting a lifetime income from the insurance company. The argument against annuities is that they represent a high price to pay for lifetime security. But they do buy lifetime security.

It makes no sense for anyone in only a 39% tax bracket to sacrifice yield to buy a tax shelter or, for that matter, to own tax-exempts.

Send your questions on finances, investments, taxes to Janeway, MEDICAL TRIBUNE, 880 Third Avenue, New York, N.Y. 10022.

PERFORMANCE. PROVEN EFFECTIVENESS WITHIN A WIDE SAFETY MARGIN.



Month after month. Year after year. The evidence continues to accumulate.

While Roche Laboratories already knows more about the performance of Librium than anyone else, we keep on learning more every day.

For example, the highly favorable benefits-to-risk ratio of Librium is a well-documented matter of record.

It's a record which shows that Librium is seldom associated with serious side effects. That Librium rarely interferes

with mental acuity. That most common side effects are dose-related and therefore — to a large extent — avoidable.

As with all CNS-acting drugs, however, patients should be cautioned against hazardous activities requiring complete mental alertness and against combined effects with alcohol.

Proven performance within a wide safety margin. Basically, that's what Librium is all about.

LIBRIUM[®]

chlordiazepoxide HCl/Roche


THE ANXIETY-SPECIFIC

Before prescribing, please consult complete product information, a summary of which follows:
Indications: Relief of anxiety and tension occurring alone or accompanying various disease states.
Contraindications: Patients with known hypersensitivity to the drug.

Warnings: Caution patients about possible combined effects with alcohol and other CNS depressants. As with all CNS-acting drugs, caution patients against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Though physical and psychological dependence have rarely been reported on recommended doses, use caution in administering to addiction-prone individuals or those who might increase dosage; withdrawal symptoms (including convulsions), following discontinuation of the drug and similar to those seen with barbiturates, have been reported. Use of any drug in pregnancy, lactation, or in women of childbearing age requires that its potential benefits be weighed against its possible hazards.
Precautions: In the elderly and debilitated, and in chil-

dren over six, limit to smallest effective dosage (initially 10 mg or less per day) to preclude ataxia or oversedation, increasing gradually as needed and tolerated. Not recommended in children under six. Though generally recommended in children under six, combination therapy with other psychotropics seems indicated, carefully consider individual pharmacologic effects, particularly in use of potential drugs such as MAO inhibitors and phenothiazines. Observe usual precautions in presence of impaired renal or hepatic function. Paradoxical reactions (e.g., excitement, stimulation and hyperactive aggressive behavior) have been reported in psychiatric patients and hyperactive aggressive children. Employ usual precautions in treatment of suicidal tendencies may be present and protective measures necessary. Variable effects on blood coagulation have been reported very rarely in patients receiving the drug and oral anticoagulants; causal relationship has not been established clinically.
Adverse Reactions: Drowsiness, ataxia and confusion may occur, especially in the elderly and debilitated.

These are reversible in most instances by proper dosage adjustment, but are also occasionally observed at the lower dosage ranges. In a few instances syncope has been reported. Also encountered are isolated instances of skin eruptions, edema, minor menstrual irregularities, nausea and constipation, extrapyramidal symptoms, increased and decreased libido—all infrequent and generally controlled with dosage reduction; changes in EEG patterns (low-voltage fast activity) may appear during and after treatment; blood dyscrasias (including agranulocytosis), jaundice and hepatic dysfunction have been reported occasionally, making periodic blood counts and liver function tests advisable during protracted therapy.
Supplied: Librium[®] Capsules containing 5 mg, 10 mg or 25 mg chlordiazepoxide HCl, Libritabs[®] Tablets containing 5 mg, 10 mg or 25 mg chlordiazepoxide.

 Roche Laboratories
Division of Hoffmann-La Roche Inc.
Nutley, New Jersey 07110

Probing for Eye Tumors



New technique to detect suspected eye tumors, utilizing ultrasound-guided gamma-ray probe and scalar counts of radioactive tracers, is employed by ophthalmologist, Dr. Michael Wainstock, at University of Michigan Hospital.

Vicki Morison Administration Manager
Isabel Hutchings Conference Manager
Charlotte Benton-Hughes Conference
Kerry Brown Technical Services Manager

Surrey TW9 2LS

tel: 081 332 2422
fax: 081 332 0939

CONSISTENT WEIGHT LOSS ON THE WAY TO THE TARGET WEIGHT



As a short-term adjunct in weight loss...
SANOREX[®]
(MAZINDOL)
 TABLETS, 1 mg and 2 mg

For Brief Summary, please see facing page.
 SAN 6-574

Wednesday, May 26, 1976

SANOREX[®] (MAZINDOL) TABLETS, 1 mg and 2 mg

Indications: In exogenous obesity, as a short-term (a few weeks) adjunct in a weight-reduction regimen based on caloric restriction. The limited usefulness of agents of this class should be measured against possible risk factors.

Contraindications: Glaucoma; hypersensitivity or idiosyncrasy to the drug; agitated states; history of drug abuse; during, or within 14 days following, administration of monoamine oxidase inhibitors (hypertensive crisis may result).

Warnings: Tolerance to many anorectic drugs may develop within a few weeks; if this occurs, do not exceed recommended dose, but discontinue drug. May impair ability to engage in potentially hazardous activities, such as operating machinery or driving a motor vehicle, and patient should be cautioned accordingly.

Drug Interactions: May decrease the hypotensive effect of guanethidine; patients should be monitored accordingly. May markedly potentiate pressor effect of exogenous catecholamines; if a patient recently taking mazindol must be given a pressor amine agent (e.g., levaterenol or isoproterenol) for shock (e.g., myocardial infarction), extreme care should be taken in monitoring blood pressure at frequent intervals and initiating pressor therapy with a low initial dose and careful titration.

Drug Dependence: Mazindol shares important pharmacologic properties with amphetamines and related stimulant drugs that have been extensively abused and can produce tolerance and severe psychological dependence. Manifestations of chronic overdosage or withdrawal with mazindol have not been determined in humans. Abstinence effects have been observed in dogs after abrupt cessation for prolonged periods. There was some self-administration of the drug in monkeys. EEG studies and "liking" scores in human subjects yielded equivocal results. While the abuse potential of mazindol has not been further defined, possibility of dependence should be kept in mind when evaluating the desirability of including the drug in a weight-reduction program.

Effects in Pregnancy: An increase in neonatal mortality and a possible increased incidence of rib anomalies in rats were observed at relatively high doses.

Although these studies have not indicated important adverse effects, the use of mazindol in pregnancy or in women who may become pregnant requires that potential benefit be weighed against possible hazard to mother and infant.

Usage in Children: Not recommended for use in children under 12 years of age.

Precautions: Insulin requirements in diabetes mellitus may be altered. Smallest amount of mazindol should be prescribed or dispensed at one time to minimize possibility of overdosage. Use cautiously in hypertension, with monitoring of blood pressure; not recommended in severe hypertension or in symptomatic cardiovascular disease including arrhythmias.

Adverse Reactions: Most commonly, dry mouth, tachycardia, constipation, nervousness, and insomnia. **Cardiovascular:** Palpitation, tachycardia. **Central Nervous System:** Overstimulation, restlessness, dizziness, insomnia, dysphoria, tremor, headache, depression, drowsiness, weakness. **Gastrointestinal:** Dryness of mouth, unpleasant taste, constipation, nausea, other gastrointestinal disturbances. **Skin:** Rash, excessive sweating, chills. **Endocrine:** Impotence, changes in libido have rarely been observed. **Eyes:** Long-term treatment with high doses in dogs resulted in some corneal opacities, reversible on cessation of medication; no such effect has been observed in humans.

Dosage and Administration: 1 mg, three times daily, one hour before meals, or 2 mg, once daily, one hour before lunch. The lowest effective dose should be used. Should GI discomfort occur, mazindol may be taken with meals.

Overdosage: There are no data as yet on acute overdosage with mazindol in humans. Manifestations of overdosage include restlessness and related symptoms, dizziness, fatigue and depression may occur in the stimulatory phase of overdosage. Cardiac effects include tachycardia, hypertension, respiratory collapse. Gastrointestinal symptoms include nausea, vomiting and abdominal cramps. Similar manifestations of overdosage may be observed. The management of acute intoxication is symptomatic. Data are not available on the treatment of acute intoxication with mazindol by gastric lavage or peritoneal dialysis, but the substance is poorly soluble except at very acid pH.


Supplied: Tablets, 1 mg and 2 mg, in packages of 100.

For prescribing or administering, see package insert for prescribing information.

Pharmaceuticals, East Hanover, N.J. 07936

MEDICAL TRIBUNE

17



On the Canaanites and Fertility, Hieroglyphics and Dayan

WE HAD JUST finished looking over some far-eastern archaeological material stored in the "bowels" of the Metropolitan and were relaxing over lunch.

"What do you consider the most interesting archaeological area?"

"Canaanite," was the unhesitating reply of Moshe Dayan, formerly Chief of Staff of the Israeli Army and now a member of the Knesset. "For me, it is most fascinating, not in terms of the aesthetics of the material—most of it is very strong, almost brutal—but because of its enormous influence on all other civilizations."

The Phoenicians' Influence

Most of us learned in Genesis that the Patriarch Abram and Sarai, his wife, left "Ur of the Chaldees to go into the land of Canaan." In history we were taught that the Phoenicians (the biblical Canaanites) inhabited the seacoast of what is now Lebanon and Israel; that the legendary Phoenicians were mariners who built their ships of the famous cedars of Lebanon. Beginning in the first thousand years of recorded history, they extended their influence almost completely around the rim of the Mediterranean, reaching into northwest Africa and western Spain. The early Canaanite period corresponded with the early bronze age, 3,000 years before Christ. Their city states included Jerusalem and the fabled Jericho, whose walls fell to the trumpets of Joshua and the remains of which one can look down upon today in an excavation which has laid bare a small sector of its ramparts.

The role of the Phoenicians in trade was not limited to their maritime reach but also to the location of Canaan on the caravan routes to Egypt and Mesopotamia. Today, archaeology is clarifying the reciprocal influences between Phoenician and Egyptian and other mideastern cultures. Professor William Foxwell Albright wrote on the seminal influence of the Canaanites on Greek higher culture, including especially art and the beginnings of rational thought. In a number of ways, "The Phoenicians became the teachers of the modern world." The "language" of Canaan is reportedly a dialect variant of biblical Hebrew. We are indebted to them for the alphabet and even for many of the rich Hebrew forms encompassed in biblical literature. Albright held that "Through Greece and Israel, Canaan exerted an incalculably great influence on the modern world."

"To what," I asked General Dayan, "do you attribute your fascination with the Canaanites?"

"They had an incredible effect upon virtually all societies of their and even our time. This is particularly true of their concept of fertility. Their efforts to assure the fertility of their crops, the fertility of their flocks, and the fertility of their women influenced almost

every society they came in contact with," he said.

I had been sensitive to the close interrelationships of the people of pre-biblical and biblical times as reflected in their common concerns with death and resurrection but I had never completely registered the implications of Moshe Dayan's remarks on the fertility cult. Heaven knows, I had handled enough fertility goddesses and been exposed to enough archaeological fertility material.

For some reason or other the comments of Dayan triggered off a new perspective on this issue. I think I know why. I had just been the recipient of quite a number of letters attacking some articles I had written on the subject of ZPG. I had always seen the issue of the right to life related to moral precepts, to personal rights and religious beliefs. But for some reason it had never occurred to me that Western concepts were so deeply rooted historically in the biblical land of Canaan and disseminated by the bold Phoenician mariners I remembered from my school days.

The Change in Our Lifetime

What an incredible inversion has occurred in history! For all of unrecorded time and for most of man's history his survival related to his "fruitfulness." When God spoke to Adam and Eve, he said: "Be fruitful and multiply." God's promise to Abraham was that his offspring would be as numerous as the stars in the heavens. This goal had previously been sought by all peoples through the polytheistic faiths of the pre-biblical times and through

the worship of fertility goddesses.

It is one thing to know, and another thing to really understand the significance of the great change that urbanization has brought to us. Initially man's survival was severed from hunting and the gathering of berries and wild grains by his success in agriculture and the domestication of animals. But with such a change, the stability and wealth of men, their tribes and societies became dependent upon fertility. In certain aspects this was true even unto our own day when the development of these United States required constant increase in numbers and infusions of new populations to till our soil, to open the lands of the west and to man our factories. But now, in our lifetime, for the first time in history, the point is made that man's survival on this planet is dependent upon the limitation of his numbers.

I have tried in the past to address this issue as dispassionately as I could. I had viewed the historic facts from certain perspectives and even resorted to computers to analyze data. What I had not counted on was the enormous emotional charge implicit in man's beliefs and faiths. The heat of the passionate debates becomes more understandable. I had never viewed the population situation from point of view of the millennial fertility cults of almost all societies and, now, the new challenge of what has become an anti-fertility cult which holds forth as man's ideal, ZPG—Zero Population Growth.

That afternoon we also touched upon Dayan's interest in Egyptian sarcophagi and General Dayan commented on his reading of the hieroglyphics on one such we had viewed together.

"You read hieroglyphics?" My surprise was evident.

"Yes," Moshe Dayan replied with a half-abashed smile, "but not like I read the *New York Times*."

EPIGRAMS—Cliché and Otherwise

The best doctors in the world are Doctor Diet, Doctor Quiet, and Doctor Merryman.

Jonathan Swift
 (1667-1745)

Polite Conversation, Dialogue 2

Cerium Nitrate 'Spectacular' In Preventing Burn Infections

Continued from page 1

during which we have treated patients with silver compounds, either silver nitrate or silver sulfadiazine," Dr. Monafó told the American Burn Association, "we noticed a striking difference in the flora on wounds as soon as cerium was introduced."

In small wounds, nearly 100% of the cultures taken after treatment with the topical agent containing cerium nitrate were sterile. In moderate sized burns, the sterile culture yield was about 75%.

"Our results to date in 45 patients could only be described as spectacular,"

Dr. Monafó declared. "Gram negative and gram positive bacteria were suppressed and we are running a percentage of sterile cultures on the order of 80% regardless of the size of wound."

Of nine patients with massive injuries who previously could not have been saved, seven have survived. Only 8% of their cultures contained any gram negative bacteria.

"Of course the bacteriological data are only part of the issue," said Dr. Monafó. "The important thing is that the clinical response of these patients has correlated with the improvement in bacteriostasis."

wine talk

By JOHN CHAMBERS
Author and Consultant to
Morrell & Company,
New York Wine Merchants

Greek and Roman Wines

I WAS REMINDED of my promise to return to the subject of ancient Greek and Roman wines by a Greek friend. He asked, "What did my ancestors drink 2000 years ago?"

Wine was extremely important in Greek culture, and some of the finest examples of Greek artistry are wine cups, pitchers, kraters, and other utensils used in the storage and service of wine. It is impossible to know with certainty how these ancient Greek wines would have tasted, but we can make some educated guesses. The practice of placing grapes on straw mats to dry out (thus concentrating their sweetness) was learned early, and consequently many of the wines were sweet.

This sweetness served to hide excessive oxidation and retard spoilage—important since the wine was stored in rag-stoppered jars. Indeed the Greek habit of adding herbs, spices, and even perfume suggests that much wine was spoiled and had to be disguised to be made palatable.

Nonetheless, there were some good wines, of which the best were the thick, concentrated, moderately sweet red wines, such as Chian and Moronean, and the naturally sweet muscats of the Greek islands. The Muscat produced on the Island of Samos today is probably the closest we can come to the storied Pramnian wine of Greek literature.

ILX B12

hematinics
of
choice

By teaspoon or tablet

- Readily assimilated
- Well tolerated
- Economical

Usual Dosage: ELIXIR—1 to 3 teaspoons daily or as directed by physician.
TABLETS—1 tablet 3 times a day or as directed by physician.
Supplied: 12 ounce bottles of Elixir; bottles of 100 Tablets.

K Kenwood Laboratories, Inc., New Rochelle, New York 10801
developers and suppliers of Cebrol and Kengesin

for
nutritional
and iron
deficiency
anemias

ILX B12

Elixir—each ounce represents: Iron and Ammonium Citrate, 18 gr • Liver Fraction 1, 3 gr • Thiamine Hydrochloride, 10 mg • Riboflavin, 4 mg • Nicotinamide, 20 mg • Cyanocobalamin (Vit. B12), 20 mcg • Alcohol 8% by volume.

Tablets—each tablet contains: Ferrous Gluconate, 5 gr • Vitamin C, 60 mg • Cyanocobalamin (Vit. B12), 10 mcg • Liver Fraction 2, 2 gr • Thiamine Hydrochloride, 2 mg • Riboflavin, 2 mg • Nicotinamide, 20 mg

ably the closest we can come to the storied Pramnian wine of Greek literature.

Increasing Sophistication

With the development of the Roman civilization, grape-growing and wine-making techniques became increasingly sophisticated. The Romans developed the concept of pruning to produce more concentrated fruit, and of grafting to combine the root vigor of one vine with the fruit qualities of another. The creation of the wooden cask and the bottle were Roman innovations.

However, most of what was drunk by the Romans never saw a bottle and was very similar to what you would find today if you were travelling through Italy,

drinking the local wine: full-flavored, robust, rather strong wines, served with a minimum of ceremony. Such wines, stored in wood or earthenware amphorae, were usually diluted with water.

The best wines were kept in small amphorae at first, and later in bottles. Resembling originally the concentrated, moderately sweet red wines of the Greeks, these became drier as storage techniques improved. Falernian, the most prized wine of Ancient Rome, was probably such a wine; heavy with tannin, it required long aging. It was said to last a hundred years and more. It was the Romans, by the way, who planted the vineyards of France and Germany; they found that grape-grow-

ing stabilized the population.


COMING UP—QUESTIONS & ANSWERS: Please send me your questions about wine. What wines would you like evaluated? When should you consume some wines? What vineyards are good to buy for laying down? Are you wondering what wines you might visit? Send in your questions, and you'll get an answer, either in the column, or from me directly.

Neostigmine Used In Treatment of Snakebite

Medical Tribune World Service

NEW DELHI, INDIA—Neostigmine has been successfully used in the treatment of snakebite unresponsive to conventional treatment, according to Lt. Col. R. N. Banerji, senior physician at Sardarjag Hospital here.

A 50-year-old patient bitten by a cobra was admitted to hospital in critical condition with respiratory and muscular paralysis and placed in an intermittent positive pressure respirator. When antivenom and steroid injections had no apparent effect, Dr. Banerji decided to try neostigmine because of the similarity between the patient's symptoms and those seen in myasthenia gravis. Normal respiration was restored and the patient discharged within a few days.



© 1976, Medical Tribune, Inc.

Indications: For the relief of cerebral and peripheral ischemia associated with arterial spasm.

Contraindications: The use of ethaverine hydrochloride is contraindicated in the presence of complete atrioventricular dissociation.

Precautions: Use with caution in patients with glaucoma. Hepatic hypersensitivity has been reported with gastrointestinal symptoms, jaundice, eosinophilia and altered liver function tests. Discontinue drug if these occur.

The safety of ethaverine hydrochloride during pregnancy or lactation has not been established; therefore it should not be used in pregnant women or in women of childbearing age unless, in the judgment of the physician, its use is deemed essential to the welfare of the patient.

Adverse Reactions: Although occurring rarely, the reported side effects of ethaverine include nausea, abdominal distress, hypotension, anorexia, constipation or diarrhea, skin rash, malaise, drowsiness, vertigo, sweating, and headache.

Dosage and Administration: One capsule three times a day.
How Supplied: 100 mg capsules in bottles of 50 and 500.

In cerebral and peripheral ischemia associated with arterial spasm

Cebrol

100mg capsules

ethaverine HCl

In cerebral ischemia: direct vasodilation of cerebral vessels; virtually no CNS effect; rare incidence of side effects permits long-term use

In peripheral vascular disorders: relaxes smooth muscles of larger blood vessels by direct effect unrelated to muscle innervation

For additional product information and professional samples, write on your letterhead to:

Professional Service Department
K KENWOOD LABORATORIES, INC.
New Rochelle, New York 10801

77% of U.S. Family Physicians Would Consider Passive Euthanasia

Continued from page 1

centarium of sophisticated life-support methods and equipment. Moreover, the Karen Ann Quinlan case, which had not yet been settled by the New Jersey State Supreme Court when the U.S. poll was taken, had abruptly—some say too abruptly—raised the level of public and professional debate over the issue of euthanasia to an unprecedented pitch. These, as well as other factors, such as the relatively traditional character of French medicine, would lead one to postulate a more open attitude towards euthanasia on the part of U.S. physicians than among their French counterparts.

The MEDICAL TRIBUNE poll did not attempt to assess the attitudes of physicians towards the many ambiguities arising in particular cases, but rather strove to establish a consensus on euthanasia's place in family medical thinking. The final decision of the New Jersey court in the Quinlan case, recommending the establishment of hospital "ethics committees"—on which family doctors will undoubtedly be called to serve—renders the results of the poll all the more compelling.

Approximately 2,200 family physicians, randomly selected from around the country, were sent ballots containing four categories of questions. The rate of response was about 30%.

Over half the physicians stated that at least once in their careers a patient

had requested that his or her suffering be "cut short," which is on a par with the experience of French general practitioners. As would be expected, more older physicians had encountered this situation than younger ones with fewer years of practice. In the middle category of physicians, 54% replied "yes" compared to 62% of French practitioners. It should be noted that this first question (see page 1) does not take into account the situation typified by the Quinlan case, where the family, not the patient, made the request. Beyond that, one is led to wonder how often physicians fail to read the signals a terminal patient may be sending. It is well known, for example, that certain types of patients, particularly those whose ethnic and educational backgrounds are different from those of their physician, "find it difficult to communicate with physicians and presumably to engage in the delicate type of negotiations required in order to obtain withdrawal of medical treatment," states Diann Crane, Ph.D., of the department of sociology, University of Pennsylvania.

One also wonders whether surgeons or other specialists might not be more likely to have encountered patients seeking relief from terminal suffering than their colleagues in general practice, who may leave the case as specialty skills become required.

Facing a terminal patient whose suffering seems unbearable, in your opinion, consider . . .

	TOTAL	35 years and less	36 to 60 years	Over 60 years
Passive euthanasia				
Yes	77%	80%	81%	73%
No	14%	11%	12%	16%
No Comment	9%	9%	7%	11%
Active euthanasia				
Yes	17%	15%	15%	18%
No	61%	59%	60%	61%
No Comment	22%	26%	25%	21%

Over three-quarters of all family doctors surveyed said they would "consider" passive euthanasia when faced with a terminal patient in "unbearable" suffering. In comparison, only slightly over half of their French counterparts answered the same—a highly significant difference. The factors previously cited—e.g., the proliferation of life-support capabilities in the U.S., the Karen Ann Quinlan case, and the traditionalism of French medicine—offer plausible explanations for these differences.

Another major difference in the outcome of the two polls lies in the patterns of response according to age. Whereas older French practitioners were more favorable towards passive euthanasia than younger ones, the current appears to run the other way among American family physicians. The disparity is hard to explain without delving into differences in national temperament, medical training and other factors.

However, one can speculate, regarding the American pattern itself,

that older physicians may retain some of the attitudes of their training years—the 1930s, 40s and 50s—when public and professional discussion of euthanasia was sparse. Up until the mid-60s, according to Dr. Stanley Joel Reiser, Assistant Professor of History of Medicine at Harvard Medical School, "uncurable disease and death meant defeat for the physician as well as the patient; both appeared to prefer the remedy of silence." The reluctance of some physicians of that generation to talk openly may lie in events surrounding World War II, when, for example, some individuals in England and the U.S. suggested in the name of mercy that incurable mental patients become the objects of euthanasia. In Nazi Germany, of course, such proposals became social policy. As a result many physicians came to believe that euthanasia could too easily become a means to express natural aggression and that the practice, even if humanely applied, could demoralize medicine and society.

For the generation coming along

after the war, such events were dim and, moreover, medical technology was introducing a whole new set of concerns. For example, intensive care monitoring, essentially unknown in the 1940s and even the 1950s, arrived on the scene. And, in 1968, the Ad Hoc Committee of the Harvard Medical School to Examine the Definition of Brain Death enunciated its revolutionary new criteria.

As to active euthanasia, the poll shows that almost two-thirds (61%)

of the Americans surveyed are opposed—significantly below the French figure (83%). It's not that a high percentage favor active euthanasia—17%, which is fairly comparable to the French findings—but rather a sizable number of American physicians opted for "no comment" (22% vs. 4%). Was this refuge sought in order to avoid expressing a disturbing attitude or does it simply reflect thoughtful indecision? Whatever the case, it would appear that U.S. physicians are potentially more flexible on the issue of active euthanasia than the French.

Some doctors accept euthanasia in certain instances cited below. In each case, do you agree with them?

Accept euthanasia	Agree	Disagree
Exclusively at the patient's request	22%	40%
At the joint request of the patient and his family	53%	10%
At the request of the family alone, the patient being unconscious	42%	20%
At the doctor's initiative	19%	49%
Do not accept euthanasia under any circumstances	38%	

The French, in analyzing their poll results, noted a difference between the percentage of practitioners who answered "do not accept euthanasia under any circumstances" (61%) and the percentage who, on an earlier question, stated that they could not "consider" passive euthanasia (36%). "There is a distance between 'considered' euthanasia and the reality of concrete situations," the French commentators wrote.

The same difference is perceptible in the responses of American family doctors: 38% ("do not accept . . .") versus 14% ("no" to "consider" passive euthanasia). In fact, the degree of shift is even greater among U.S. physicians. Thus, it is possible that many physicians who accept euthanasia in

theory might find it repugnant in practice.

A noteworthy difference between French and American responses is that while fully 25% of French practitioners accept euthanasia "at the doctor's initiative," only 13% of American family doctors agree with this concept. Whether this disparity could be attributable to the autocratic, tradition-bound nature of French society, contrasting with the somewhat more open nature of our own, must remain speculative.

In addition, whereas the fewest number of French physicians agreed with "at the joint request of patient and family," that same category proved the most acceptable to U.S. family doctors.

Would you wish physicians had greater freedom to shorten the suffering of a terminal patient?

	TOTAL	35 years and less	36 to 60 years	Over 60 years
Yes	48%	41%	48%	48%
No	43%	47%	44%	42%
No Comment	9%	12%	8%	10%

Almost half the American doctors surveyed expressed a desire for "greater freedom" to shorten the suffering of terminal patients; only about a third of French practitioners were so inclined. It is possible that many family physicians who are willing to "consider" passive euthanasia (77%) shun the freedom to act, which would be consistent with the earlier observation of a gap between theory and practice. On the other hand, it's also possible that some of these physicians believe that sufficient freedom already exists, but that institutionalization of it would be detrimental to the individual doctor-patient relationship. How the respondents reacted to the New


Jersey State Supreme Court's decision—which gave physicians greater freedom in cases like the Quinlan one—remains unknown.

What kind of picture emerges from the results of this poll? One can certainly discern a flexibility on the part of most family doctors on the issue of euthanasia. At the same time one senses hesitation and uncertainty, prompted, perhaps, by a wish to avoid becoming morally and legally entrapped. Certainly few physicians would sit tight for "euthanasia on demand." Nor do they wish autonomy for themselves. The path towards a solution, in the view of the American family doctor, lies through the trees.

Apresoline[®].. (hydralazine) relaxes arterioles to solve the major hemodynamic problem in hypertension

Abnormally high peripheral resistance is the major hemodynamic problem with most hypertensives.

Apresoline reduces peripheral resistance and lowers blood pressure through a direct relaxation of arteriolar smooth muscle.



high peripheral resistance: common attribute of most hypertensives

Because high peripheral resistance is the major hemodynamic disturbance found in most patients with essential hypertension,^{1,2} the therapeutic goal should be reduction of total peripheral resistance and a return to more normal peripheral circulation.^{1,2}

Hence, vasodilating drugs "...offer a physiologically rational approach to the therapy of hypertension."³ In addition, "...vasodilators [combined with a sympathetic inhibitor] are the most predictable and specific drugs for reversing the hemodynamic abnormality of most hypertensive patients."⁴

the only oral agent that deals directly with this problem

Apresoline (hydralazine), the only currently approved oral antihypertensive with vasodilating action, decreases peripheral resistance — regardless of its cause — and, hence, arterial pressure by relaxing arteriolar smooth muscle. Accompanying the fall in blood pressure is a rise in cardiac output and rate. Apresoline also maintains or increases renal and cerebral blood flow.

a different and complementary pharmacologic approach

Different in action from all other oral antihypertensives and compatible with most of them, Apresoline can play a significant role in a variety of therapeutic combinations.

Such combinations, according to Freis,⁵ with each component representing a different antihypertensive mecha-

nism, provide the most effective way to control blood pressure. This approach may also permit lower drug dosages.

the problem of postural hypotension minimized

Nickerson⁶ describes the action of Apresoline as follows:

"A preferential effect on arterioles, as compared to veins, allows the increase in cardiac output and minimizes postural hypotension; the latter is much less than that produced by agents blocking sympathetic nerves."

Continued on following page

Apresoline[®] hydrochloride (hydralazine hydrochloride)

TABLETS

INDICATIONS

Essential hypertension, alone or as an adjunct.

CONTRAINDICATIONS

Hypersensitivity; coronary artery disease; mitral valvular rheumatic heart disease.

WARNINGS

Hydralazine may produce in a few patients a clinical picture simulating systemic lupus erythematosus. In such patients hydralazine should be discontinued unless the benefit to risk determination requires continued antihypertensive therapy with

this drug. Symptoms and signs usually regress when the drug is discontinued but relapses have been detected many years later. Long-term treatment with steroids may be necessary.

Complete blood counts, L.E. cell preparations and antinuclear antibody titer determinations are indicated before and periodically during prolonged therapy even though patient is asymptomatic. These studies are also indicated in the presence of any unexplained symptoms.

A positive antinuclear antibody titer and/or positive L.E. cell reaction requires that the physician carefully weigh the indications of the test results against the benefits to be derived from antihypertensive therapy with hydralazine.

Use MAO inhibitors with caution.

Usage in Pregnancy

The drug should be used only when, in the judgment of the physician, it is deemed essential to the welfare of the patient.

PRECAUTIONS

Use cautiously in suspected coronary artery or other cardiovascular diseases, cerebral vascular accidents, and advanced renal damage. Postural hypotension may occur, and the pressor response to epinephrine may be reduced.

Peripheral neuritis, evidenced by paresthesias, numbness, and tingling, has been observed. Published evidence suggests an antipyridoxine effect and addition of pyridoxine to the regimen if symptoms develop.

Blood dyscrasias, consisting of reduction in hemoglobin and red cell count, leukopenia, agranulocytosis, and purpura, have been reported rarely. If such abnormalities develop, discontinue

therapy. Periodic blood counts are advised during prolonged therapy.

ADVERSE REACTIONS

Common: Headache; palpitations; soreness; nausea; vomiting; diarrhea; tachycardia; angina pectoris. Less frequent: Nasal congestion; flushing; lacrimation; conjunctivitis; peripheral neuritis, evidenced by paresthesias, numbness, and tingling; edema; dizziness; tremors; muscle cramps; psychotic reactions; characterized by depression, disorientation, or anxiety; hypersensitivity (including rash, urticaria, pruritus, fever, chills, arthralgia, eosinophilia, and rarely, hepatitis); constipation; difficulty in micturition; dyspnea; paralytic ileus; lymphadenopathy; apoplexy; blood dyscrasias, consisting of reduction in hemoglobin and red cell count, leukopenia,

agranulocytosis, and purpura; hypotension; paradoxical pressor response.

DOSEAGE

Initiate therapy in gradually increasing dosages; adjust according to individual response. Start with 10 mg 4 times daily for the first 2 to 4 days.

Tablets, 25 mg (deep blue, dry-coated) and 50 mg (light blue, dry-coated); bottles of 30, 60, 100, 500 and 1000.

Tablets, 100 mg (peach, dry-coated); bottles of 100.

Consult complete literature before prescribing.

both may be considered. However, when combining therapy, individual titration is essential to insure the lowest possible therapeutic dose of each drug.

HOW SUPPLIED

Tablets, 10 mg (pale yellow, dry-coated); bottles of 30, 60, 100 and 1000.

Tablets, 25 mg (deep blue, dry-coated) and 50 mg (light blue, dry-coated); bottles of 30, 60, 100, 500 and 1000.

Tablets, 100 mg (peach, dry-coated); bottles of 100.

Consult complete literature before prescribing.

CIBA Pharmaceutical Company
Division of CIBA-GEIGY Corporation
Summit, New Jersey 07901

C I B A

Wicki Morrison Administration Manager
Isabel Hutchings Conference Manager
Charlotte Benton-Hughes Conference Services
Technical Services

Surrey TW20 2LS

Tel: 081 332 2422
Fax: 081 332 0939

مكتبة

C I B A